

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
11 April 2002 (11.04.2002)

PCT

(10) International Publication Number
WO 02/28837 A1(51) International Patent Classification: C07D 215/18,
215/22, 215/14, 215/38, C07F 7/10, C07D 215/48, 409/04,
471/04, 215/36, 405/04, 409/12, 401/12, 491/04, 495/04,
A61K 31/4791003, F-9277 Issy-les-Moulineaux (FR). **LESAGE, Anne, Simone, Josephine** [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE).

(21) International Application Number: PCT/EP01/11135

(74) Agent: VAN BORM, Werner; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE).

(22) International Filing Date:
25 September 2001 (25.09.2001)

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
00203419.7 2 October 2000 (02.10.2000) EP

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (for all designated States except US):
JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **MABIRE, Dominique, Jean-Pierre** [FR/FR]; Janssen-Cilag S.A., 1, rue Camille Desmoulins, TSA 91003, F-92777 Issy-les-Moulineaux (FR). **VENET, Marc, Gaston** [FR/FR]; Janssen-Cilag S.A., 1, rue Camille Desmoulins, TSA 91003, F-92777 Issy-les-Moulineaux (FR). **COUPA, Sophie** [FR/FR]; Janssen-Cilag S.A., 1, rue Camille Desmoulins, TSA 91003, F-92777 Issy-les-Moulineaux (FR). **PONCELET, Alain, Philippe** [FR/FR]; Janssen-Cilag S.A., 1, rue Camille Desmoulins, TSA

Declaration under Rule 4.17:

— of inventorship (Rule 4.17(iv)) for US only

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS

(57) Abstract: The present invention concerns compounds of formula. In a preferable embodiment, X represents O; R¹ represents C₁₋₆alkyl; cycloC₃₋₁₂alkyl or (cycloC₃₋₁₂alkyl)C₁₋₆alkyl, wherein one or more hydrogen atoms in a C₁₋₆alkyl-moiety or in a cycloC₃₋₁₂alkyl-moiety optionally may be replaced by C₁₋₆alkyloxy, aryl, halo or thienyl; R² represents hydrogen; halo; C₁₋₆alkyl or amino; R³ and R⁴ each independently represent hydrogen or C₁₋₆alkyl; or R² and R³ may be taken together to form -R²-R³-, which represents a bivalent radical of formula -Z₄-CH₂-CH₂-CH₂- or -Z₄-CH₂-CH₂- with Z₄ being O or NR¹¹ wherein R¹¹ is C₁₋₆alkyl; and wherein each bivalent radical is optionally substituted with C₁₋₆alkyl; or R³ and R⁴ may be taken together to form a bivalent radical of formula -CH₂-CH₂-CH₂-CH₂-; R⁵ represents hydrogen; Y represents O, and aryl represents phenyl optionally substituted with halo. The invention also relates to the use of a compound according to the invention as a medicament and in the manufacture of a medicament for treating or preventing glutamate-induced diseases of the central nervous system, as well as formulations comprising such a compound and processes for preparing such a compound.

-1-

METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS

The present invention is concerned with quinoline and quinolinone derivatives showing
5 metabotropic glutamate receptor antagonistic activity and their preparation; it further
relates to compositions comprising them, as well as their use as a medicine.


The neurotransmitter glutamate is considered to be the major excitatory
neurotransmitter in the mammalian central nervous system. The binding of this
10 neurotransmitter to metabotropic glutamate receptors (mGluRs), which are a subfamily
of the G-protein-coupled receptors and which comprise 8 distinct subtypes of mGluRs,
namely mGluR1 through mGluR8, activates a variety of intracellular second messenger
systems. The mGluRs can be divided into 3 groups based on amino acid sequence
homology, the second messenger system utilized by the receptors and the
15 pharmacological characteristics. Group I mGluRs, which comprises mGluR subtype 1
and 5, couple to phospholipase C and their activation leads to intracellular calcium-ion
mobilization. Group II mGluRs (mGluR2 and 3) and group III mGluRs (mGluR4, 6, 7
and 8) couple to adenylyl cyclase and their activation causes a reduction in second
messenger cAMP and as such a dampening of the neuronal activity. Treatment with
20 Group I mGluR antagonists has been shown to translate in the presynapse into a
reduced release of neurotransmitter glutamate and to decrease the glutamate-mediated
neuronal excitation via postsynaptic mechanisms. Since a variety of
pathophysiological processes and disease states affecting the central nervous system are
thought to be due to excessive glutamate induced excitation of the central nervous
25 system neurons, Group I mGluR antagonists could be therapeutically beneficial in the
treatment of central nervous system diseases.

WO 99/26927 discloses antagonists of Group I mGlu receptors for treating neurological
diseases and disorders, based – among others – on a quinoline structure.

30 WO 99/03822 discloses bicyclic metabotropic glutamate receptor ligands, none of them
based on a quinoline or quinolinone structure.


-2-

The present invention concerns compounds of formula



an *N*-oxide form, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochemically isomeric form thereof, wherein

- 5 X represents O; C(R⁶)₂ with R⁶ being hydrogen, aryl or C₁₋₆alkyl optionally substituted with amino or mono- or di(C₁₋₆alkyl)amino; S or N-R⁷ with R⁷ being amino or hydroxy;
- 10 R¹ represents C₁₋₆alkyl; aryl; thienyl; quinoliny; cycloC₃₋₁₂alkyl or (cycloC₃₋₁₂alkyl)C₁₋₆alkyl, wherein the cycloC₃₋₁₂alkyl moiety optionally may contain a double bond and wherein one carbon atom in the cycloC₃₋₁₂alkyl moiety may be replaced by an oxygen atom or an NR⁸-moiety with R⁸ being hydrogen, benzyl or C₁₋₆alkyloxycarbonyl; wherein one or more hydrogen atoms in a C₁₋₆alkyl-moiety or in a cycloC₃₋₁₂alkyl-moiety optionally may be replaced by C₁₋₆alkyl, hydroxyC₁₋₆alkyl, haloC₁₋₆alkyl, aminoC₁₋₆alkyl, hydroxy, C₁₋₆alkyloxy,
- 15 arylC₁₋₆alkyloxy, halo, C₁₋₆alkyloxycarbonyl, aryl, amino, mono- or di(C₁₋₆alkyl)amino, C₁₋₆alkyloxycarbonylamino, halo, piperazinyl, pyridinyl, morpholinyl, thienyl or a bivalent radical of formula -O-, -O-CH₂-O or -O-CH₂-CH₂-O-;
- or a radical of formula (a-1)



20

a-1

wherein Z₁ is a single covalent bond, O, NH or CH₂;

Z₂ is a single covalent bond, O, NH or CH₂;

n is an integer of 0, 1, 2 or 3;

25

and wherein each hydrogen atom in the phenyl ring independently may optionally be replaced by halo, hydroxy, C₁₋₆alkyl,

C₁₋₆alkyloxy or hydroxyC₁₋₆alkyl;

or X and R¹ may be taken together with the carbon atom to which X and R¹ are attached to form a radical of formula (b-1), (b-2) or (b-3);

-3-



b-1



b-2



b-3

- R^2 represents hydrogen; halo; cyano; C_{1-6} alkyl; C_{1-6} alkyloxy; C_{1-6} alkylthio; C_{1-6} alkylcarbonyl; C_{1-6} alkyloxy carbonyl; C_{1-6} alkylcarbonyloxy C_{1-6} alkyl; C_{2-6} alkenyl; hydroxy C_{2-6} alkenyl; C_{2-6} alkynyl; hydroxy C_{2-6} alkynyl; tri(C_{1-6} alkyl)silane C_{2-6} alkynyl; amino; mono- or di(C_{1-6} alkyl)amino; mono- or di(C_{1-6} alkyloxy C_{1-6} alkyl)amino; mono- or di(C_{1-6} alkylthio C_{1-6} alkyl)amino; aryl; aryl C_{1-6} alkyl; aryl C_{2-6} alkynyl; C_{1-6} alkyloxy C_{1-6} alkylamino C_{1-6} alkyl; aminocarbonyl optionally substituted with C_{1-6} alkyl, C_{1-6} alkyloxy C_{1-6} alkyl, C_{1-6} alkyloxy carbonyl C_{1-6} alkyl or pyridinyl C_{1-6} alkyl; a heterocycle selected from thienyl, furanyl, pyrrolyl, thiazolyl, oxazolyl, imidazolyl, isothiazolyl, isoxazolyl, pyrazolyl, pyridyl, pyrazinyl, pyridazinyl, pyrimidinyl, piperidinyl and piperazinyl, optionally N-substituted with C_{1-6} alkyloxy C_{1-6} alkyl, morpholinyl, thiomorpholinyl, dioxanyl or dithianyl; a radical $-NH-C(=O)R^9$ wherein R^9 represents C_{1-6} alkyl optionally substituted with cyclo C_{3-12} alkyl, C_{1-6} alkyloxy, C_{1-6} alkyloxy carbonyl, aryl, aryloxy, thienyl, pyridinyl, mono- or di(C_{1-6} alkyl)amino, C_{1-6} alkylthio, benzylthio, pyridinylthio or pyrimidinylthio; cyclo C_{3-12} alkyl; cyclohexenyl; amino; arylcyclo C_{3-12} alkylamino; mono- or di(C_{1-6} alkyl)amino; mono- or di(C_{1-6} alkyloxy carbonyl C_{1-6} alkyl)amino; mono- or di(C_{1-6} alkyloxy carbonyl)amino; mono- or di(C_{2-6} alkenyl)amino; mono- or di(aryl C_{1-6} alkyl)amino; mono- or diarylamino; aryl C_{2-6} alkenyl; furanyl C_{2-6} alkenyl; piperidinyl; piperazinyl; indolyl; furyl; benzofuryl; tetrahydrofuryl; indenyl; adamantyl; pyridinyl; pyrazinyl; aryl; aryl C_{1-6} alkylthio or a radical of formula (a-1); a sulfonamid $-NH-SO_2-R^{10}$ wherein R^{10} represents C_{1-6} alkyl, mono- or poly halo C_{1-6} alkyl, aryl C_{1-6} alkyl, aryl C_{2-6} alkenyl, aryl, quinolinyl, isoxazolyl or di(C_{1-6} alkyl)amino;
- R^3 and R^4 each independently represent hydrogen; halo; hydroxy; cyano; C_{1-6} alkyl; C_{1-6} alkyloxy; C_{1-6} alkyloxy C_{1-6} alkyl; C_{1-6} alkylcarbonyl; C_{1-6} alkyloxy carbonyl;

-4-

C₂₋₆alkenyl; hydroxyC₂₋₆alkenyl; C₂₋₆alkynyl; hydroxyC₂₋₆alkynyl;
tri(C₁₋₆alkyl)silaneC₂₋₆alkynyl; amino; mono- or di(C₁₋₆alkyl)amino; mono- or
di(C₁₋₆alkyloxyC₁₋₆alkyl)amino; mono- or di(C₁₋₆alkylthioC₁₋₆alkyl)amino; aryl;
morpholinylC₁₋₆alkyl or piperidinylC₁₋₆alkyl; or

- 5 R² and R³ may be taken together to form -R²-R³-, which represents a bivalent radical of
formula -(CH₂)₃-, -(CH₂)₄-, -(CH₂)₅-, -(CH₂)₆-, -CH=CH-CH=CH-,
-Z₄-CH=CH-, -CH=CH-Z₄-, -Z₄-CH₂-CH₂-CH₂-, -CH₂-Z₄-CH₂-CH₂-,
-CH₂-CH₂-Z₄-CH₂-,
-CH₂-CH₂-CH₂-Z₄-, -Z₄-CH₂-CH₂-, -CH₂-Z₄-CH₂- or -CH₂-CH₂-Z₄-, with Z₄ being
10 O, S, SO₂ or NR¹¹ wherein R¹¹ is hydrogen, C₁₋₆alkyl, benzyl or
C₁₋₆alkyloxycarbonyl; and wherein each bivalent radical is optionally substituted
with C₁₋₆alkyl.

or R³ and R⁴ may be taken together to form a bivalent radical of formula

-CH=CH-CH=CH- or -CH₂-CH₂-CH₂-CH₂-;

- 15 R⁵ represents hydrogen; cycloC₃₋₁₂alkyl; piperidinyl; oxo-thienyl; tetrahydrothienyl,
arylC₁₋₆alkyl; C₁₋₆alkyloxyC₁₋₆alkyl; C₁₋₆alkyloxycarbonylC₁₋₆alkyl or C₁₋₆alkyl
optionally substituted with a radical C(=O)NR_xR_y, in which R_x and R_y, each
independently are hydrogen, cycloC₃₋₁₂alkyl, C₂₋₆alkynyl or C₁₋₆alkyl optionally
substituted with cyano, C₁₋₆alkyloxy, C₁₋₆alkyloxycarbonyl, furanyl, pyrrolidinyl,
20 benzylthio, pyridinyl, pyrrolyl or thienyl;

Y represents O or S;

or Y and R⁵ may be taken together to form =Y-R⁵- which represents a radical of
formula

-CH=N-N= (c-1);

- 25 -N=N-N= (c-2); or

-N-CH=CH- (c-3);

aryl represents phenyl or naphthyl optionally substituted with one or more substituents
selected from halo, hydroxy, C₁₋₆alkyl, C₁₋₆alkyloxy, phenyloxy, nitro, amino, thio,
C₁₋₆alkylthio, haloC₁₋₆alkyl, polyhaloC₁₋₆alkyl, polyhaloC₁₋₆alkyloxy,
30 hydroxyC₁₋₆alkyl, C₁₋₆alkyloxyC₁₋₆alkyl, aminoC₁₋₆alkyl, mono- or
di(C₁₋₆alkyl)amino; mono- or di(C₁₋₆alkyl)aminoC₁₋₆alkyl, cyano, -CO-R¹²,
-CO-OR¹³, -NR¹³SO₂R¹², -SO₂-NR¹³R¹⁴, -NR¹³C(O)R¹², -C(O)NR¹³R¹⁴, -SOR¹²,
-SO₂R¹²; wherein each R¹², R¹³ and R¹⁴ independently represent C₁₋₆alkyl;
cycloC₃₋₆alkyl; phenyl; phenyl substituted with halo, hydroxy, C₁₋₆alkyl,
35 C₁₋₆alkyloxy, haloC₁₋₆alkyl, polyhaloC₁₋₆alkyl, furanyl, thienyl, pyrrolyl,
imidazolyl, thiazolyl or oxazolyl;

and when the $R^1-C(=X)$ moiety is linked to another position than the 7 or 8 position, then said 7 and 8 position may be substituted with R^{15} and R^{16} wherein either one or both of R^{15} and R^{16} represents C_{1-6} alkyl, C_{1-6} alkyloxy or R^{15} and R^{16} taken together may form a bivalent radical of formula $-CH=CH-CH=CH-$.

5

As used in the foregoing definitions and hereinafter C_{1-6} alkyl as a group or part of a group encompasses the straight and branched chain saturated hydrocarbon radicals having from 1 to 6 carbon atoms such as, for example, methyl, ethyl, propyl, butyl, pentyl or hexyl; C_{2-6} alkenyl as a group or part of a group encompasses the straight and
10 branched chain hydrocarbon radicals having from 2 to 6 carbon atoms and having a double bond such as ethenyl, propenyl, butenyl, pentenyl, hexenyl, 3-methylbutenyl and the like; C_{2-6} alkynyl as a group or part of a group defines straight or branched chain hydrocarbon radicals having from 2 to 6 carbon atoms and having a triple bond such as ethynyl, propynyl, butynyl, pentynyl, hexynyl, 3-methylbutynyl and the like;
15 cyclo C_{3-6} alkyl encompasses monocyclic alkyl ring structures such as cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl; cyclo C_{3-12} alkyl encompasses mono-, bi- or tricyclic alkyl ring structures and is generic to for example cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, norbornanyl, adamantyl.

20 The term halo is generic to fluoro, chloro, bromo and iodo. As used in the foregoing and hereinafter, polyhalo C_{1-6} alkyl as a group or part of a group is defined as mono- or polyhalosubstituted C_{1-6} alkyl, in particular methyl with one or more fluoro atoms, for example, difluoromethyl or trifluoromethyl. In case more than one halogen atoms are attached to an alkyl group within the definition of polyhalo C_{1-6} alkyl, they may be the
25 same or different.

When any variable, e.g. aryl, occurs more than one time in any constituent, each definition is independent.

30 When any bond is drawn into a ring structure, it means that the corresponding substituent may be linked to any atom of said ring structure. This means for instance that the $R^1-C(=X)$ moiety may be linked to the quinoline or quinolinone moiety in position 5, 6, 7, 8 but also position 3 or position 4.

35 For therapeutic use, salts of the compounds of formula (I-A) and (I-B) are those wherein the counterion is pharmaceutically acceptable. However, salts of acids and bases which are non-pharmaceutically acceptable may also find use, for example, in the

-6-

preparation or purification of a pharmaceutically acceptable compound. All salts, whether pharmaceutically acceptable or not are included within the ambit of the present invention.

- 5 The pharmaceutically acceptable addition salts as mentioned hereinabove are meant to comprise the therapeutically active non-toxic acid addition salt forms which the compounds of formula (I-A) and (I-B) are able to form. The latter can conveniently be obtained by treating the base form with such appropriate acids as inorganic acids, for example, hydrohalic acids, e.g. hydrochloric, hydrobromic and the like; sulfuric acid;
10 nitric acid; phosphoric acid and the like; or organic acids, for example, acetic, propanoic, hydroxyacetic, 2-hydroxypropanoic, 2-oxopropanoic, oxalic, malonic, succinic, maleic, fumaric, malic, tartaric, 2-hydroxy-1,2,3-propanetricarboxylic, methanesulfonic, ethanesulfonic, benzenesulfonic, 4-methylbenzenesulfonic, cyclohexanesulfamic, 2-hydroxybenzoic, 4-amino-2-hydroxybenzoic and the like acids.
15 Conversely the salt form can be converted by treatment with alkali into the free base form.

- The compounds of formula (I-A) and (I-B) containing acidic protons may be converted into their therapeutically active non-toxic metal or amine addition salt forms by
20 treatment with appropriate organic and inorganic bases. Appropriate base salt forms comprise, for example, the ammonium salts, the alkali and earth alkaline metal salts, e.g. the lithium, sodium, potassium, magnesium, calcium salts and the like, salts with organic bases, e.g. primary, secondary and tertiary aliphatic and aromatic amines such as methylamine, ethylamine, propylamine, isopropylamine, the four butylamine
25 isomers, dimethylamine, diethylamine, diethanolamine, dipropylamine, diisopropylamine, di-n-butylamine, pyrrolidine, piperidine, morpholine, trimethylamine, triethylamine, tripropylamine, quinuclidine, pyridine, quinoline and isoquinoline, the benzathine, *N*-methyl-D-glucamine, 2-amino-2-(hydroxymethyl)-1,3-propanediol, hydrabamine salts, and salts with amino acids such as, for example,
30 arginine, lysine and the like. Conversely the salt form can be converted by treatment with acid into the free acid form.

- The term addition salt also comprises the hydrates and solvent addition forms which the compounds of formula (I-A) and (I-B) are able to form. Examples of such forms are
35 e.g. hydrates, alcoholates and the like.

-7-

The term "quaternary amine" as used hereinbefore defines the quaternary ammonium salts which the compounds of formula (I-A) and (I-B) are able to form by reaction between a basic nitrogen of a compound of formula (I-A) or (I-B) and an appropriate quaternizing agent, such as, for example, an optionally substituted alkylhalide, arylhalide or arylalkylhalide, e.g. methyl iodide or benzyl iodide. Other reactants with good leaving groups may also be used, such as alkyl trifluoromethanesulfonates, alkyl methanesulfonates, and alkyl p-toluenesulfonates. A quaternary amine has a positively charged nitrogen. Pharmaceutically acceptable counterions include chloro, bromo, iodo, trifluoroacetate and acetate. The counterion of choice can be introduced using ion exchange resins.

It will be appreciated that some of the compounds of formula (I-A) and (I-B) and their *N*-oxides, salts, quaternary amines and stereochemically isomeric forms may contain one or more centers of chirality and exist as stereochemically isomeric forms.

The term "stereochemically isomeric forms" as used hereinbefore defines all the possible stereoisomeric forms which the compounds of formula (I-A) and (I-B), and their *N*-oxides, salts, quaternary amines or physiologically functional derivatives may possess. Unless otherwise mentioned or indicated, the chemical designation of compounds denotes the mixture of all possible stereoisomeric forms, said mixtures containing all diastereomers and enantiomers of the basic molecular structure as well as each of the individual isomeric forms of formula (I-A) and (I-B) and their *N*-oxides, salts, solvates or quaternary amines substantially free, i.e. associated with less than 10 %, preferably less than 5 %, in particular less than 2% and most preferably less than 1 % of the other isomers. Stereochemically isomeric forms of the compounds of formula (I-A) and (I-B) are obviously intended to be embraced within the scope of the present invention. The same applies to the intermediates as described herein, used to prepare end products of formula (I-A) and (I-B).

The terms *cis* and *trans* are used herein in accordance with Chemical Abstracts nomenclature.

In some compounds of formula (I-A) and (I-B) and in the intermediates used in their preparation, the absolute stereochemical configuration has not been determined. In these cases, the stereoisomeric form which was first isolated is designated as "A" and the second as "B", without further reference to the actual stereochemical configuration. However, said "A" and "B" stereoisomeric forms can be unambiguously characterized

-8-

by physicochemical characteristics such as their optical rotation in case "A" and "B" have an enantiomeric relationship. A person skilled in the art is able to determine the absolute configuration of such compounds using art-known methods such as, for example, X-ray diffraction. In case "A" and "B" are stereoisomeric mixtures, they can be further separated whereby the respective first fractions isolated are designated "A1" and "B1" and the second as "A2" and "B2", without further reference to the actual stereochemical configuration.

The *N*-oxide forms of the present compounds are meant to comprise the compounds of formula (I-A) and (I-B) wherein one or several nitrogen atoms are oxidized to the so-called *N*-oxide.

Some of the compounds of formula (I-A) and (I-B) may also exist in their tautomeric form. Such forms although not explicitly indicated in the above formula are intended to be included within the scope of the present invention.


Whenever used hereinafter, the term "compounds of formula (I-A) and (I-B)" is meant to also include their *N*-oxide forms, their salts, their quaternary amines and their stereochemically isomeric forms. Of special interest are those compounds of formula (I-A) and (I-B) which are stereochemically pure.

An interesting group of compounds are those compounds of formula (I-A) and (I-B) wherein

X represents O; $C(R^6)_2$ with R^6 being hydrogen or aryl ; or $N-R^7$ with R^7 being amino or hydroxy;

R^1 represents C_{1-6} alkyl, aryl; thienyl; quinolinyl; cyclo C_{3-12} alkyl or (cyclo C_{3-12} alkyl) C_{1-6} alkyl, wherein the cyclo C_{3-12} alkyl moiety optionally may contain a double bond and wherein one carbon atom in the cyclo C_{3-12} alkyl moiety may be replaced by an oxygen atom or an NR^8 -moiety with R^8 being benzyl or C_{1-6} alkyloxycarbonyl ; wherein one or more hydrogen atoms in a C_{1-6} alkyl-moiety or in a cyclo C_{3-12} alkyl-moiety optionally may be replaced by C_{1-6} alkyl, halo C_{1-6} alkyl, hydroxy, C_{1-6} alkyloxy, aryl C_{1-6} alkyloxy, halo, aryl, mono- or di(C_{1-6} alkyl)amino, C_{1-6} alkyloxycarbonylamino, halo, piperazinyl, pyridinyl, morpholinyl, thienyl or a bivalent radical of formula $-O-$ or $-O-CH_2-CH_2-O-$; or a radical of formula (a-1)

-9-



a-1

wherein Z_1 is a single covalent bond, O or CH_2 ;

Z_2 is a single covalent bond, O or CH_2 ;

n is an integer of 0, 1, or 2 ;

and wherein each hydrogen atom in the phenyl ring independently may optionally be replaced by halo or hydroxy;

or X and R^1 may be taken together with the carbon atom to which X and R^1 are attached to form a radical of formula (b-1), (b-2) or (b-3);



b-1



b-2



b-3

R^2 represents hydrogen; halo; cyano; C_{1-6} alkyl; C_{1-6} alkyloxy; C_{1-6} alkylthio; C_{1-6} alkylcarbonyl; C_{1-6} alkyloxycarbonyl; C_{2-6} alkenyl; hydroxy C_{2-6} alkenyl; C_{2-6} alkynyl; hydroxy C_{2-6} alkynyl; tri(C_{1-6} alkyl)silane C_{2-6} alkynyl; amino; mono- or di(C_{1-6} alkyl)amino; mono- or di(C_{1-6} alkyloxy C_{1-6} alkyl)amino; mono- or di(C_{1-6} alkylthio C_{1-6} alkyl)amino; aryl; aryl C_{1-6} alkyl; aryl C_{2-6} alkynyl; C_{1-6} alkyloxy C_{1-6} alkylamino C_{1-6} alkyl; aminocarbonyl optionally substituted with C_{1-6} alkyloxycarbonyl C_{1-6} alkyl ; a heterocycle selected from thienyl, furanyl, thiazolyl and piperidinyl, optionally N-substituted with morpholinyl or thiomorpholinyl; a radical $-\text{NH}-\text{C}(=\text{O})\text{R}^9$ wherein R^9 represents C_{1-6} alkyl optionally substituted with cyclo C_{3-12} alkyl, C_{1-6} alkyloxy, C_{1-6} alkyloxycarbonyl, aryl, aryloxy, thienyl, pyridinyl, mono- or di(C_{1-6} alkyl)amino, C_{1-6} alkylthio, benzylthio, pyridinylthio or pyrimidinylthio; cyclo C_{3-12} alkyl; cyclohexenyl; amino; arylcyclo C_{3-12} alkylamino; mono- or di(C_{1-6} alkyl)amino; mono- or di(C_{1-6} alkyloxycarbonyl C_{1-6} alkyl)amino; mono- or di(C_{1-6} alkyloxycarbonyl)amino; mono- or di(C_{2-6} alkenyl)amino; mono- or di(aryl C_{1-6} alkyl)amino; mono- or diarylamino; aryl C_{2-6} alkenyl; furanyl C_{2-6} alkenyl; piperididynyl; piperazinyl; indolyl; furyl; benzofuryl; tetrahydrofuryl; indenyl; adamantyl; pyridinyl; pyrazinyl; aryl or a radical of formula (a-1) ;

-10-

- a sulfonamid -NH-SO₂-R¹⁰ wherein R¹⁰ represents C₁₋₆alkyl, mono- or poly haloC₁₋₆alkyl, arylC₁₋₆alkyl or aryl;
- R³ and R⁴ each independently represent hydrogen; C₁₋₆alkyl; C₁₋₆alkyloxyC₁₋₆alkyl; C₁₋₆alkyloxy carbonyl; or
- 5 R² and R³ may be taken together to form -R²-R³-, which represents a bivalent radical of formula -(CH₂)₄-, -(CH₂)₅-, -Z₄-CH=CH-, -Z₄-CH₂-CH₂-CH₂- or -Z₄-CH₂-CH₂-, with Z₄ being O, S, SO₂ or NR¹¹ wherein R¹¹ is hydrogen, C₁₋₆alkyl, benzyl or C₁₋₆alkyloxy carbonyl; and wherein each bivalent radical is optionally substituted with C₁₋₆alkyl;
- 10 or R³ and R⁴ may be taken together to form a bivalent radical of formula -CH=CH-CH=CH- or -CH₂-CH₂-CH₂-CH₂-;
- R⁵ represents hydrogen; piperidinyl; oxo-thienyl; tetrahydrothienyl, arylC₁₋₆alkyl; C₁₋₆alkyloxy carbonylC₁₋₆alkyl or C₁₋₆alkyl optionally substituted with a radical C(=O)NR_xR_y, in which R_x and R_y, each independently are hydrogen,
- 15 cycloC₃₋₁₂alkyl, C₂₋₆alkynyl or C₁₋₆alkyl optionally substituted with cyano, C₁₋₆alkyloxy or C₁₋₆alkyloxy carbonyl;
- Y represents O or S;
- or Y and R⁵ may be taken together to form =Y-R⁵- which represents a radical of formula
- 20 -CH=N-N= (c-1); or
-N=N-N= (c-2);
- aryl represents phenyl or naphthyl optionally substituted with one or more substituents selected from halo, C₁₋₆alkyloxy, phenyloxy, mono- or di(C₁₋₆alkyl)amino and cyano;
- 25 and when the R¹-C(=X) moiety is linked to another position than the 7 or 8 position, then said 7 and 8 position may be substituted with R¹⁵ and R¹⁶ wherein either one or both of R¹⁵ and R¹⁶ represents C₁₋₆alkyl or R¹⁵ and R¹⁶ taken together may form a bivalent radical of formula -CH=CH-CH=CH-.
- 30 A further most interesting group of compounds comprises those compounds of formula (I-A) and (I-B) wherein X represents O;
- R¹ represents C₁₋₆alkyl; cycloC₃₋₁₂alkyl or (cycloC₃₋₁₂alkyl)C₁₋₆alkyl, wherein one or more hydrogen atoms in a C₁₋₆alkyl-moiety or in a cycloC₃₋₁₂alkyl-moiety optionally may be replaced by C₁₋₆alkyloxy, aryl, halo or thienyl;
- 35 R² represents hydrogen; halo; C₁₋₆alkyl or amino;
- R³ and R⁴ each independently represent hydrogen or C₁₋₆alkyl; or

-11-

R^2 and R^3 may be taken together to form $-R^2-R^3-$, which represents a bivalent radical of formula $-Z_4-CH_2-CH_2-CH_2-$ or $-Z_4-CH_2-CH_2-$ with Z_4 being O or NR^{11} wherein R^{11} is C_{1-6} alkyl; and wherein each bivalent radical is optionally substituted with C_{1-6} alkyl;

5 or R^3 and R^4 may be taken together to form a bivalent radical of formula $-CH_2-CH_2-CH_2-CH_2-$;

R^5 represents hydrogen;


Y represents O; and

aryl represents phenyl optionally substituted with halo.


10

A further interesting group of compounds comprises those compounds of formula (I-A) and (I-B) wherein the $R^1-C(=X)$ moiety is linked to the quinoline or quinolinone moiety in position 6.

15 In order to simplify the structural representation of some of the present compounds and intermediates in the following preparation procedures, the quinoline or the quinolinone moiety will hereinafter be represented by the symbol Q.




The compounds of formula (I-A) or (I-B), wherein X represents O, said compounds
20 being represented by formula (I_{A/B}-a), can be prepared by oxidizing an intermediate of formula (II) in the presence of a suitable oxidizing agent, such as potassium permanganate, and a suitable phase-transfer catalyst, such as tris(dioxa-3,6-heptyl)amine, in a suitable reaction-inert solvent, such as for example dichloromethane.




25 Compounds of formula (I_{A/B}-a) may also be prepared by reacting an intermediate of formula (III) with an intermediate of formula (IV), wherein W_1 represents a halo atom, e.g. bromo, in the presence of butyl lithium and a suitable reaction-inert solvent, such as for example tetrahydrofuran.

-12-




Alternatively, compounds of formula (I_{A/B}-a) may also be prepared by reacting an intermediate of formula (V) with an intermediate of formula (IV) in the presence of butyl lithium and a suitable reaction-inert solvent, such as for example tetrahydrofuran.



5


Compounds of formula (I_{A/B}-a), wherein the R¹ substituent is linked to the carbonyl moiety via an oxygen atom, said R¹ substituent being represented by O-R^{1a} and said compounds by formula (I_{A/B}-a-1), can be prepared by reacting an intermediate of formula (VI) with an intermediate of formula (VII) in the presence of a suitable acid, such as sulfuric acid.

10



Compounds of formula (I-A), wherein R² represents methylcarbonyl, said compounds being represented by formula (I-A-1), can be prepared by reacting an intermediate of formula (VIII) in the presence of a suitable acid, such as hydrochloric acid, and a suitable reaction-inert solvent, such as for example tetrahydrofuran.

15



The compounds of formula (I) may also be converted into each other following art-known transformations.

20

Compounds of formula (I-A) wherein R² is a halo atom, such as chloro, can be converted into a compound of formula (I-A), wherein R² is another halo atom, such as fluoro or iodo, by reaction with a suitable halogenating agent, such as for example

potassium fluoride or sodium iodide, in the presence of a suitable reaction-inert solvent, e.g. dimethyl sulfoxide or acetonitrile and optionally in the presence of acetyl chloride.

Compounds of formula (I-A), wherein R^2 is a suitable leaving group, such as a halo atom, e.g. chloro, iodo, said leaving group being represented by W^2 and said compounds by (I-A-2), can be converted into a compound of formula (I-A) wherein R^2 is cyano, said compound being represented by formula (I-A-3), by reaction with a suitable cyano-introducing agent, such as for example trimethylsilanecarbonitrile, in the presence of a suitable base such as *N,N*-diethylethanamine and a suitable catalyst, such as for example tetrakis(triphenylphosphine)palladium.

Compounds of formula (I-A-2) can also be converted into a compound of formula (I-A-4) by reaction with $C_{2-6}alkynyltri(C_{1-6}alkyl)silane$ in the presence of CuI, an appropriate base, such as for example *N,N*-diethylethanamine, and an appropriate catalyst, such as for example tetrakis(triphenylphosphine)palladium. Compounds of formula (I-A-4) can on their turn be converted into a compound of formula (I-A-5) by reaction with potassium fluoride in the presence of a suitable acid such as acetic acid, or by reaction with a suitable base, such as potassium hydroxide, in the presence of a suitable reaction-inert solvent, such as an alcohol, e.g. methanol and the like.

Compounds of formula (I-A-2) can also be converted into a compound of formula (I-A-6) by reaction with an intermediate of formula (IX) in the presence of CuI, a suitable base, such as for example *N,N*-diethylethanamine, and a suitable catalyst such as tetrakis(triphenylphosphine)palladium.

Compounds of formula (I-A-2) can also be converted into a compound wherein R^2 is $C_{1-6}alkyl$, said compound being represented by formula (I-A-8) in the presence of a suitable alkylating agent, such as for example $Sn(C_{1-6}alkyl)_4$, or into a compound wherein R^2 is $C_{2-6}alkenyl$, said compound being represented by formula (I-A-9) in the presence of a suitable alkenylating agent, such as for example $Sn(C_{2-6}alkenyl)(C_{1-6}alkyl)_3$, both reactions in the presence of a suitable catalyst, such as for example tetrakis(triphenylphosphine)palladium and a reaction-inert solvent, such as for example toluene or dioxane.

Compounds of formula (I-A-2) can also be converted into a compound of formula (I-A-7) wherein Z represents O or S, by reaction with an intermediate of formula (X)

-14-


optionally in the presence of a suitable base such as dipotassium carbonate and a reaction-inert solvent, such as *N,N*-dimethyl formamide.

- 5 Compounds of formula (I-A-2) can also be converted into a compound of formula (I-A), wherein R^2 is C_{1-6} alkyloxycarbonyl, said compound being represented by formula (I-A-10) and a compound of formula (I-A), wherein R^2 is hydrogen, said compound being represented by formula (I-A-11), by reaction with a suitable alcohol of formula C_{1-6} alkylOH and CO in the presence of a suitable catalyst, such as for example
10 palladium(II)acetate, triphenylphosphine, a suitable base such as dipotassium carbonate and a reaction-inert solvent, such as *N,N*-dimethylformamide.

Compounds of formula (I-A-11) can also be prepared by reacting a compound of formula (I-A-2) with Zn in the presence of a suitable acid such as acetic acid.


- 15 Compounds of formula (I-A-2) can also be converted into a compound of formula (I-A), wherein R^2 is aminocarbonyl substituted with C_{1-6} alkyloxycarbonyl C_{1-6} alkyl, said compound being represented by formula (I-A-12), by reaction with an intermediate of formula $H_2N-C_{1-6}alkyl-C(=O)-O-C_{1-6}alkyl$ in the presence of CO, a suitable catalyst
20 such as tetrakis(triphenylphosphine)palladium, a suitable base, such as for example *N,N*-diethylethanamine, and a suitable reaction-inert solvent, such as for example toluene.

-15-




-16-

Compounds of formula (I-A-2) can also be converted into a compound of formula (I-A) wherein R^2 is aryl or a heterocycle selected from the group described in the definition of R^2 hereinabove, said R^2 being represented by R^{2a} and said compound by formula (I-A-13) by reaction with an intermediate of formula (XI), (XII) or (XIII) in the presence of a suitable catalyst such as for example tetrakis(triphenylphosphine)palladium and a suitable reaction-inert solvent, such as for example dioxane.




Compounds of formula (I-A-2) can also be converted into a compound of formula (I-B), wherein Y and R^5 are taken together to form a radical of formula (b-1) or (b-2), said compound being represented by formula (I-B-1) or (I-B-2), by reaction with hydrazincarboxaldehyde or sodium azide in a suitable reaction-inert solvent, such as an alcohol, e.g. butanol, or *N,N*-dimethylformamide.




Compounds of formula (I-A-11) can be converted into the corresponding *N*-oxide, represented by formula (I-A-14), by reaction with a suitable peroxide, such as 3-chloro-benzenecarboxylic acid, in a suitable reaction-inert solvent, such as for

-17-

example methylene chloride. Said compound of formula (I-A-14) can further be converted into a compound of formula (I-B), wherein R^3 is hydrogen, said compound being represented by formula (I-B-3), by reaction with 4-methyl-benzene sulfonyl chloride in the presence of a suitable base, such as for example dipotassium carbonate and a suitable reaction-inert solvent, such as for example methylene chloride.




Compounds of formula (I-B-3) can also be prepared from a compound of formula (I-A), wherein R^2 is C_{1-6} alkyloxy, said compound being represented by formula (I-A-15), by reaction with a suitable acid, such as hydrochloric acid, in the presence of a suitable reaction-inert solvent, such as for example tetrahydrofuran.




Compounds of formula (I-B-3) can be converted into a compound of formula (I-B), wherein R^5 represents C_{1-6} alkyl, said compound being represented by formula (I-B-4), by reaction with an appropriate alkylating agent, such as for example an intermediate of formula (XIV), wherein W_3 represents a suitable leaving group such as a halo atom e.g. iodo, in the presence of potassium tert. butoxide and in the presence of a suitable reaction-inert solvent, such as for example tetrahydrofuran.

-18-




Compounds of formula (I-B-3) can also be converted into a compound of formula (I-B), wherein R⁵ is C₁₋₆alkyloxycarbonylC₁₋₆alkyl or arylC₁₋₆alkyl, said R⁵ being represented by R^{5a} and said compound being represented by formula (I-B-5), by reaction with an intermediate of formula (XV), wherein W₄ represents a suitable leaving group, such as a halo atom, e.g. bromo, chloro and the like, in the presence of a suitable base, such as for example sodium hydride and a suitable reaction-inert solvent, such as for example *N,N*-dimethylformamide.



- 10 Compounds of formula (I-A-2) can also be converted into a compound of formula (I-B), wherein R⁵ is hydrogen and Y is S, said compound being represented by formula (I-B-6), by reaction with H₂N-C(=S)-NH₂ in the presence of a suitable base, such as potassium hydroxide, and a suitable reaction-inert solvent, such as an alcohol, for example ethanol, or water. Compounds of formula (I-B-6) can further be converted


-19-

into a compound of formula (I-A), wherein R^2 is C_{1-6} alkylthio, said compound being represented by formula (I-A-16), by reaction with a suitable C_{1-6} alkylhalide, such as for example C_{1-6} alkyliodide, in the presence of a suitable base, such as dipotassium carbonate, and a suitable solvent, such as for example acetone.



Compounds of formula (I_{A/B}-a) can be converted into a compounds of formula (I-A) or (I-B), wherein X is $N-R^7$, said compound being represented by formula (I_{A/B}-b), by reaction with an intermediate of formula (XVI), optionally in the presence of a suitable base, such as for example *N,N*-diethylethanamine, and in the presence of a suitable reaction-inert solvent, such as an alcohol, e.g. ethanol.

10



As already indicated in the preparation procedure of compounds of formula (I-A-13) described above, the compounds of formula (I) may also be converted to the corresponding *N*-oxide forms following art-known procedures for converting a trivalent nitrogen into its *N*-oxide form. Said *N*-oxidation reaction may generally be carried out by reacting the starting material of formula (I) with an appropriate organic or inorganic peroxide. Appropriate inorganic peroxides comprise, for example, hydrogen peroxide, alkali metal or earth alkaline metal peroxides, e.g. sodium peroxide, potassium peroxide; appropriate organic peroxides may comprise peroxy acids such as, for example, benzenecarboxoperoxy acid or halo substituted benzenecarboxoperoxy acid, e.g. 3-chlorobenzenecarboxoperoxy acid, peroxyalkanoic acids, e.g. peroxyacetic acid, alkylhydroperoxides, e.g. *tert*-butyl hydroperoxide. Suitable solvents are, for example, water, lower alkanols, e.g. ethanol and the like, hydrocarbons, e.g. toluene, ketones, e.g. 2-butanone, halogenated hydrocarbons, e.g. dichloromethane, and mixtures of such solvents.


25

Some of the intermediates and starting materials used in the above reaction procedures are commercially available, or may be synthesized according to procedures already described in the literature.


30

-20-


Intermediates of formula (II) may be prepared by reacting an intermediate of formula (XVII) with an intermediate of formula (XVIII), wherein W_5 represents a suitable leaving group such as a halo atom, e.g. chloro, bromo and the like, in the presence of magnesium, diethylether and a suitable reaction-inert solvent, such as diethylether.




Intermediates of formula (XVII) may be prepared by oxidizing an intermediate of formula (XIX) in the presence of a suitable oxidizing agent, such as MnO_2 , and a suitable reaction-inert solvent, such as methylene chloride.



Intermediates of formula (XIX) can be prepared by reducing an intermediate of formula (XX) in the presence of a suitable reducing agent such as lithium aluminium hydride, and a suitable reaction-inert solvent, such as tetrahydrofuran.




Intermediates of formula (XX), wherein Q represents a quinoline moiety optionally substituted in position 3 with $\text{C}_{1-6}\text{alkyl}$ and wherein the carbonyl moiety is placed in position 6, said intermediates being represented by formula (XX-a), can be prepared by reacting an intermediate of formula (XXI) with an intermediate of formula (XXII) in the presence of sodium 3-nitro-benzene sulfonate, a suitable acid, such as sulfuric acid, and a suitable alcohol, e.g. methanol, ethanol, propanol, butanol and the like.




Alternatively, intermediates of formula (II) can also be prepared by reacting an intermediate of formula (XXIII) with an intermediate of formula (XXIV), wherein W_6 is a suitable leaving group, such as a halo atom, e.g. bromo, chloro and the like, in the presence of a suitable agent, such as butyl lithium and a suitable reaction-inert solvent, such as tetrahydrofuran.


-21-




- Intermediates of formula (XXIII) can be prepared by oxidizing an intermediate of formula (XXV) using the Moffatt Pfitzner or Swern oxidation (dimethylsulfoxide adducts with dehydrating agents e.g. DCC, Ac₂O, SO₃, P₄O₁₀, COCl₂ or Cl-CO-COCl) in an inert solvent such as methylene chloride.



Intermediates of formula (XXV) can be prepared by reducing an intermediate of formula (XXVI) in the presence of a suitable reducing agent, such as for example lithium aluminium hydride and a suitable reaction-inert solvent, such as benzene.




- Intermediates of formula (XXVI) can be prepared from an intermediate of formula (XXVII) by esterification in the presence of a suitable alcohol, such as methanol, ethanol, propanol, butanol and he like, and a suitable acid, such as sulfuric acid.




- Intermediates of formula (XXVII), wherein R¹ represents a radical of formula (a-1) with Z₁ being O, Z₂ being CH₂ and n being 1, said intermediates being represented by formula (XXVII-a), can be prepared by reducing an intermediate of formula (XXVIII) in the presence of a suitable reducing agent such as hydrogen, and a suitable catalyst, such as palladium on charcoal, and a suitable acid such as acetic acid. When R¹ of intermediate (XXVII) represents an optionally substituted phenyl moiety, it can also be converted into an optionally substituted cyclohexyl moiety by reduction in the presence of a suitable reducing agent such as rhodium on Al₂O₃, and a suitable reaction-inert solvent, such as tetrahydrofuran.


-22-




- Intermediates of formula (IV), wherein Q represents a quinoline moiety substituted in position 2 with halo, e.g. chloro, said intermediates being represented by formula (IV-a), can be prepared by reacting an intermediate of formula (IV), wherein Q represents a quinolinone moiety with R^5 being hydrogen, said intermediate being represented by formula (IV-b), in the presence of POCl_3 .




- Intermediates of formula (IV-a), wherein R^4 is hydrogen, said intermediates being represented by formula (IV-a-1), can also be prepared by reacting an intermediate of formula (XXIX) with POCl_3 in the presence of *N,N*-dimethylformamide (Vilsmeier-Haack formylation followed by cyclization).



- Intermediates of formula (XXIX) may be prepared by reacting an intermediate of formula (XXX) with an intermediate of formula (XXXI), wherein W_7 represents a suitable leaving group, such as a halo atom, e.g. chloro, in the presence of a suitable base, such as for example *N,N*-diethylethanamine, and a suitable reaction-inert solvent, such as methylene chloride.




Intermediates of formula (IV-a) can be converted into an intermediate of formula (IV-c) by reaction with an intermediate of formula (XXXII) in the presence of a suitable reaction-inert solvent, such as an alcohol, e.g. methanol and the like.



Intermediates of formula (IV-a) can also be converted into an intermediate of formula (IV-d-1) by reaction with a suitable amine of formula (XXXIII-a), wherein Z₃ and Z₄ each independently represent hydrogen, C₁₋₆alkyl, C₁₋₆alkyloxyC₁₋₆alkyl, C₁₋₆alkylthioC₁₋₆alkyl or into an intermediate of formula (IV-d-2) by reaction with a suitable amine of formula (XXXIII-b), wherein Z₃ and Z₄ are taken together to form a heterocycle as defined hereinabove in the definition of R² provided that the heterocycle comprises at least one nitrogen atom, in the presence of a suitable base, such as for example dipotassium carbonate, and a reaction-inert solvent, such as *N,N*-dimethylformamide.

10

15




Intermediates of formula (IV-a), wherein R³ represents CH₂-CH₂-CH₂-Cl, said intermediates being represented by formula (IV-a-2), can also be converted into an intermediate of formula (IV), wherein R² and R³ are taken together to form a bivalent radical of formula -O-CH₂-CH₂-CH₂-, said intermediate being represented by formula (IV-e-1), by reaction with a suitable acid, such as hydrochloric acid and the like.

20


Intermediates of formula (IV-a-2) can also be converted into an intermediate of formula (IV), wherein R² and R³ are taken together to form a bivalent radical of formula

-24-


-S-CH₂-CH₂-CH₂-, said intermediate being represented by formula (IV-e-2), by reaction with H₂N-C(=S)-NH₂ in the presence of a suitable reaction-inert solvent, such as an alcohol, e.g. ethanol.



- 5 Intermediates of formula (V) may be prepared by reacting an intermediate of formula (XXVII) with an intermediate of formula CH₃-NH-O-CH₃ in the presence of 1,1'-carbonyldiimidazole and a suitable reaction-inert solvent, such as methylene chloride.




- 10 Intermediates of formula (VII), wherein Q represents a quinoline moiety, in particular a quinoline moiety wherein R² is ethyl, R³ is methyl and R⁴ is hydrogen, and the carboxyl moiety is placed in position 6, said intermediates being represented by formula (VII-a), can be prepared by reaction an intermediate of formula (XXXIV) in the presence of a suitable aldehyde, such as CH₃-CH₂-CH(=O), (CH₂O)_n, ZnCl₂, FeCl₃ and a suitable reaction-inert solvent, such as an alcohol, for example ethanol.



- 20 Intermediates of formula (VIII) can be prepared by reacting an intermediate of formula (XXXV) with an intermediate of formula (XXXVI) in the presence of a suitable

-25-

catalyst, such as for example tetrakis(triphenylphosphine)palladium and a suitable reaction-inert solvent, such as for example dioxane.



5

Still some other preparations can be devised, some of them are disclosed further in this application with the Examples.

- 10 Pure stereoisomeric forms of the compounds and the intermediates of this invention may be obtained by the application of art-known procedures. Diastereomers may be separated by physical separation methods such as selective crystallization and chromatographic techniques, e.g. liquid chromatography using chiral stationary phases. Enantiomers may be separated from each other by the selective crystallization of their
- 15 diastereomeric salts with optically active acids. Alternatively, enantiomers may be separated by chromatographic techniques using chiral stationary phases. Said pure stereoisomeric forms may also be derived from the corresponding pure stereoisomeric forms of the appropriate starting materials, provided that the reaction occurs stereo-
- 20 selectively or stereospecifically. Preferably, if a specific stereoisomer is desired, said compound will be synthesized by stereoselective or stereospecific methods of preparation. These methods will advantageously employ chirally pure starting materials. Stereoisomeric forms of the compounds of formula (I) are obviously intended to be included within the scope of the invention.
- 25 A stereoisomer of a compound of formula (I-A) or (I-B) such as a *cis* form, may be converted into another stereoisomer such as the corresponding *trans* form by reacting the compound with a suitable acid, such as hydrochloric acid, in the presence of a suitable reaction-inert solvent, such as for example tetrahydrofuran.
- 30 The compounds of formula (I-A) and (I-B), the *N*-oxides, the pharmaceutically acceptable addition salts, the quaternary amines and the stereochemically isomeric forms thereof show mGluR antagonistic activity, more in particular Group I mGluR

antagonistic activity. The Group I mGluR specifically antagonized by the present compounds is the mGluR1.

The mGluR1 antagonistic activity of the present compounds can be demonstrated in the Signal transduction on cloned rat mGluR1 in CHO cells test and the Cold allodynia test
5 in rats with a Bennett ligation, as described hereinafter.

Due to their mGluR antagonistic activity, more in particular their Group I mGluR antagonistic activity and even more in particular, their mGluR1 antagonistic activity, the compounds of formula (I-A) or (I-B), their *N*-oxides, pharmaceutically acceptable
10 addition salts, quaternary amines and stereochemically isomeric forms are useful in the treatment or prevention of glutamate-induced diseases of the central nervous system. Diseases in which a role for glutamate has been demonstrated include drug addiction or abstinence (dependence, opioid tolerance, opioid withdrawal), hypoxic, anoxic and ischemic injuries (ischemic stroke, cardiac arrest), pain (neuropathic pain, inflammatory
15 pain, hyperalgesia), hypoglycemia, diseases related to neuronal damage, brain trauma, head trauma, spinal cord injury, myelopathy, dementia, anxiety, schizophrenia, depression, impaired cognition, amnesia, bipolar disorders, conduct disorders, Alzheimer's disease, vascular dementia, mixed (Alzheimer's and vascular) dementia, Lewy Body disease, delirium or confusion, Parkinson's disease, Huntington's disease,
20 Down syndrome, epilepsy, aging, Amyotrophic Lateral Sclerosis, multiple sclerosis, AIDS (Acquired Immune Deficiency Syndrome) and AIDS related complex (ARC).

In view of the utility of the compounds of formula (I-A) and (I-B), there is provided a method of treating warm-blooded animals, including humans, suffering from
25 glutamate-induced diseases of the central nervous system. Said method comprises the administration, preferably oral administration, of an effective amount of a compound of formula (I-A) or (I-B), a *N*-oxide form, a pharmaceutically acceptable addition salt, a quaternary amine or a possible stereoisomeric form thereof, to warm-blooded animals, including humans.

In view of the above described pharmacological properties, the compounds of formula (I-A) and (I-B) or any subgroup thereof, their *N*-oxides, pharmaceutically acceptable addition salts, quaternary amines and stereochemically isomeric forms, may be used as a medicine. In particular, the use of a compound of formula (I-A) and (I-B) in the
35 manufacture of a medicament for treating or preventing glutamate-induced diseases of

-27-

the central nervous system is provided. More in particular, the present compounds may be used as neuroprotectants, analgesics or anticonvulsants.

5 The present invention also provides compositions for treating or preventing glutamate-induced diseases of the central nervous system comprising a therapeutically effective amount of a compound of formula (I-A) or (I-B) and a pharmaceutically acceptable carrier or diluent.

10 Therefore, the compounds of the present invention or any subgroup thereof may be formulated into various pharmaceutical forms for administration purposes. As appropriate compositions there may be cited all compositions usually employed for systemically administering drugs. To prepare the pharmaceutical compositions of this invention, a therapeutically effective amount of a particular compound, in base or addition salt form, as the active ingredient is combined in intimate admixture with a
15 pharmaceutically acceptable carrier, which carrier may take a wide variety of forms depending on the form of preparation desired for administration. These pharmaceutical compositions are desirably in unitary dosage form suitable, preferably, for administration orally, rectally, topically, percutaneously or by parenteral injection. For example, in preparing the compositions in oral dosage form, any of the usual
20 pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, emulsions, elixirs and solutions; or solid carriers such as starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules and tablets. Because of their ease in administration, tablets and capsules
25 represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. For parenteral compositions, the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included. Injectable solutions, for example, may be prepared in which the carrier comprises saline solution, glucose
30 solution or a mixture of saline and glucose solution. Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed. Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations. As appropriate compositions for topical application there may be cited all compositions usually employed for
35 topically administering drugs e.g. creams, gel, dressings, shampoos, tinctures, pastes, ointments, salves, powders and the like. In the compositions suitable for percutaneous administration, the carrier optionally comprises a penetration enhancing agent and/or a

-28-

suitable wetting agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not cause a significant deleterious effect to the skin. Said additives may facilitate the administration to the skin and/or may be helpful for preparing the desired compositions. These compositions may be administered in
5 various ways, e.g., as a transdermal patch, as a spot-on, as an ointment.

It is especially advantageous to formulate the aforementioned pharmaceutical compositions in unit dosage form for ease of administration and uniformity of dosage. Unit dosage form as used in the specification and claims herein refers to physically
10 discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. Examples of such unit dosage forms are tablets (including scored or coated tablets), capsules, pills, suppositories, powder packets, wafers, injectable solutions or suspensions, teaspoonfuls, tablespoonfuls and
15 the like, and segregated multiples thereof.

The therapeutically effective dose or frequency of administration depends on the particular compound of formula (I-A) or (I-B) used, the particular condition being treated, the severity of the condition being treated, the age, weight, sex, fed or fasted
20 state, and the general physical condition of the particular patient as well as other medication the individual may be taking, as is well known to those skilled in the art. Furthermore, it is evident that said therapeutically effective dose or the effective daily dose may be lowered or increased depending on the response of the treated subject and/or depending on the evaluation of the physician prescribing the compounds of the
25 instant invention. It may be appropriate to administer the required dose as two, three, four or more sub-doses at appropriate intervals throughout the day. Said sub-doses may be formulated as unit dosage forms.

The following examples are intended to illustrate the present invention.


30

Experimental part

Hereinafter, "DMF" is defined as *N,N*-dimethylformamide, "DIPE" is defined as diisopropylether, "DMSO" is defined as dimethylsulfoxide, "BHT" is defined as 2,6-bis(1,1-dimethylethyl)-4-methylphenol, and "THF" is defined as tetrahydrofuran.

35

-29-


Preparation of the intermediatesExample A1

A mixture of 4-(1-methylethoxy)benzoic acid (0.083 mol) and Rh/Al₂O₃ 5% (10g) in THF (220ml) was hydrogenated at 50°C (under 3 bar pressure of H₂) for 1 night. The mixture was filtered over celite, washed with THF and evaporated. Yield: 16g of intermediate 1 (100%).

Example A2

Preparation of 2-ethyl-3-methyl-6-quinolinecarboxylic acid (interm. 2)

A mixture of 4-aminobenzoic acid (0.299 mol) in ethanol (250ml) was stirred at room temperature. ZnCl₂ (0.0367 mol) and (CH₂O)_n (10g) were added. FeCl₃·6H₂O (0.5 mol) was added portionwise and the temperature rose till 60-65°C. Propanal (30ml) was added dropwise over a 2 hours period. The mixture was refluxed for 2 hours and kept at room temperature for 12 hours. The mixture was poured into water and filtered through celite. The filtrate was acidified till pH=7 with HCl 6N and the mixture was evaporated till dryness. The residue was used without further purification. Yield : 56.1g of 2-ethyl-3-methyl-6-quinolinecarboxylic acid (interm. 2).


Example A3

Pentanoyl chloride (0.2784 mol) was added at 5°C to a mixture of 4-bromobenzenamine (0.232 mol) and *N,N*-diethylethanamine (0.2784 mol) in CH₂Cl₂ (400ml). The mixture was stirred at room temperature overnight, poured out into water and extracted with CH₂Cl₂. The organic layer was separated, washed with a concentrated NH₄OH solution and water, dried (MgSO₄), filtered and the solvent was evaporated. The residue (60g) was crystallized from diethylether. The precipitate was filtered off and dried. The residue (35g, 63%) was taken up in CH₂Cl₂. The organic layer was separated, washed with a 10% K₂CO₃ solution, washed with water, dried (MgSO₄), filtered and the solvent was evaporated. Yield: 30g of intermediate (3) (54%).

-30-

Example A4

Preparation of




(interm. 4)

- A mixture of 6-bromo-2(1*H*)-quinolinone (0.089 mol) in POCl₃ (55ml) was stirred at 60°C overnight, then at 100°C for 3 hours and the solvent was evaporated. The residue was taken up in CH₂Cl₂, poured out into ice water, basified with NH₄OH conc., filtered over celite and extracted with CH₂Cl₂. The organic layer was separated, dried (MgSO₄), filtered and the solvent was evaporated. Yield: 14.5g of intermediate (4) (67%).

Example A5


a) Preparation of



(interm. 5)

- DMF (37ml) was added dropwise at 10°C under N₂ flow to POCl₃ (108ml). After complete addition, the mixture was allowed to warm to room temperature. *N*-(4-bromophenyl)butanamide (0.33 mol) was added portionwise. The mixture was stirred at 85°C overnight, then allowed to cool to room temperature and poured out on ice (exothermic reaction). The precipitate was filtered off, washed with a small amount of water and dried (vacuum). The residue was washed with EtOAc/diethyl ether and dried. Yield: 44.2g of intermediate (5) (50%).

b) Preparation of




(interm. 6)

- A mixture of intermediate (5) (0.162 mol) in methanol (600ml), and a solution of methanol sodium salt in methanol at 35% (154ml) was stirred and refluxed overnight. The mixture was poured out on ice. The precipitate was filtered off, washed with a small amount of water and taken up in CH₂Cl₂. K₂CO₃ 10% was added and the mixture was extracted with CH₂Cl₂. The organic layer was separated, washed with water, dried (MgSO₄), filtered and the solvent was evaporated. Yield: 31.9g of intermediate (6) (74%).

Example A6

Preparation of



(interm. 7)

- 1,1'-Carbonylbis-1*H*-imidazole (0.074 mol) was added portionwise to a mixture of 4-methoxycyclohexanecarboxylic acid (0.063 mol) in CH₂Cl₂ (200ml). The mixture was stirred at room temperature for 1 hour. Then *N*-methoxymethanamine (0.074 mol)

-31-


was added. The mixture was stirred at room temperature overnight, poured out into H₂O and extracted with CH₂Cl₂. The organic layer was separated, washed several times with H₂O, dried (MgSO₄), filtered and the solvent was evaporated. Yield: 12.6g of interm. 7.

5 Example A7

- a) A mixture of 6-fluoro-4-oxo-4H-1-benzopyran-2-carboxylic acid (0.30mol) in acetic acid (400ml) was hydrogenated with Pd/C (3g) as a catalyst. After uptake of H₂ (3 equiv), the catalyst was filtered off. The filtrate was evaporated. The residue was stirred in petroleum ether. The precipitate was filtered off and dried (vacuum; 70°C).
- 10 After recrystallization from CHCl₃/CH₃OH, the precipitate was filtered off and dried (vacuum; 80°C and high vacuum; 85°C). Yield: 8.8 g of 6-fluoro-3,4-dihydro-2H-1-benzopyran-2-carboxylic acid (interm. 8) (15.0%).
- b) A mixture of intermediate (8) (0.255 mol) in ethanol (400ml) and H₂SO₄ (5ml) was stirred and refluxed for 8 hours. The solvent was evaporated till dryness. The residue
- 15 was dissolved in CH₂Cl₂. The organic layer was separated, washed with K₂CO₃ 10%, dried (MgSO₄), filtered and the solvent was evaporated. Yield: 45g of ethyl 6-fluoro-3,4-dihydro-2H-1-benzopyran-2-carboxylate (interm. 9) (79%).
- c) Reaction under N₂. A mixture of sodium bis(2-methoxyethoxy)aluminumhydride, 70 wt % solution in methylbenzene 3.4M (0.44 mol) in benzene (150 ml) (reflux) was
- 20 added dropwise during 1 hour to a refluxed mixture of interm. 9 (0.22 mol) and benzene (600 ml). After stirring for 2.5 hours at reflux temperature, the mixture was cooled to ±15°C. The mixture was decomposed by adding dropwise ethanol (30 ml) and water (10 ml). This mixture was poured out onto ice/water and this mixture was acidified with concentrated hydrochloric acid. This mixture was extracted with diethyl
- 25 ether (500 ml). The separated organic layer was washed with water, dried, filtered and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent : CHCl₃). The desired fraction was collected and the eluent was evaporated. Yield: 34 g of 6-fluoro-3,4-dihydro-2H-1-benzopyran-2-methanol (interm. 10) (85%).
- 30 d) Reaction under N₂. To a stirred and cooled (-60°C; 2-propanone/CO₂ bath) mixture of ethanedioyl dichloride (0.1 mol) in CH₂Cl₂ (350 ml) was added sulfinylbis[methane] (30 ml) during 10 minutes. After stirring 10 minutes, a mixture of interm. 10 in CH₂Cl₂ (90 ml) was added during 5 minutes. After stirring for 15 minutes, N,N-diethylethanamine (125 ml) was added. When the mixture was warmed up to
- 35 room temperature, it was poured out in water. The product was extracted with CH₂Cl₂. The organic layer was washed with water, HCl (1M), water, NaHCO₃ (10%) and water,

dried and evaporated. The residue was dissolved in diethyl ether, washed with water, dried, filtered and evaporated. The residue was purified by column chromatography over silica gel (eluent : CHCl_3). The desired fraction was collected and the eluent was evaporated. Yield: 21.6 g of 6-fluoro-3,4-dihydro-2H-1-benzopyran-2-carboxaldehyde


(interm. 11)




nButyllithium 1.6M (0.056 mol) was added slowly at -70°C to a solution of intermediate (5) (0.046 mol) in THF (100ml). The mixture was stirred at -70°C for 30 minutes. A suspension of interm. 11 (0.056 mol) in THF (100ml) was added slowly. The mixture was stirred at -70°C for 1 hour, then brought to room temperature, poured out into H_2O and extracted with EtOAc. The organic layer was separated, dried (MgSO_4), filtered and the solvent was evaporated. The residue (21 g) was purified by column chromatography over silica gel (eluent: cyclohexane/EtOAc 80/10; 15-35 μm). The pure fractions were collected and the solvent was evaporated. Yield: 9.5g of interm. 12 (55%).

15 Example A8

a) Preparation of




and



A mixture of intermediate (5) (0.1127 mol), 2-methoxyethanamine (0.2254 mol) and K_2CO_3 (0.2254 mol) in DMF (500ml) was stirred at 120°C for 15 hours and then cooled. The solvent was evaporated. The residue was taken up in CH_2Cl_2 and H_2O . The organic layer was separated, dried (MgSO_4), filtered and the solvent was evaporated till dryness. The residue (33.53g) was purified by column chromatography over silica gel (eluent: $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}$ 99.5/0.5; 15-40 μm). Two fractions were collected and their solvents were evaporated. Yield: 5.7g of interm. 14 (38%) and interm. 13 (34%).

b) Preparation of



A mixture of intermediate (5) (0.0751 mol), thiomorpholine (0.0891 mol) and K_2CO_3 (0.15 mol) in DMF (200ml) was stirred at 120°C for 12 hours. The solvent was evaporated till dryness. The residue was taken up in CH_2Cl_2 and H_2O . The organic

-33-


layer was separated, dried (MgSO_4), filtered and the solvent was evaporated. The residue (26g) was purified by column chromatography over silica gel (eluent: cyclohexane/EtOAc 80/20; 20–45 μm). Two fractions were collected and their solvents were evaporated. The two fractions were combined. Yield: 9.4g of interm. 15 (37%); mp. 82°C.

Example A9

- a) 4-Aminobenzoic acid (0.219 mol) was added to a solution of sodium 3-nitrobenzenesulfonate (0.118 mol) in H_2SO_4 70% (230ml) and the mixture was stirred and refluxed. 2-propene-1,1-diol, 2-methyl-, diacetate (0.216 mol) was added dropwise and the mixture was refluxed for 4 hours. Ethanol (200ml) was added and the mixture was stirred at 80°C for 48 hours. The mixture was evaporated, the residue was poured into ice water/ NH_4OH and extracted with CH_2Cl_2 . The organic layer was dried (MgSO_4) and evaporated. The residue was purified by column chromatography over silica gel (eluent : CH_2Cl_2 /2-propanol 99/1). The pure fractions were collected and evaporated. Yield : 21g of ethyl 3-methyl-6-quinolinecarboxylate (interm. 16) (45%).
- b) Interm. 16 (0.098 mol) in THF (270ml) was added at 0°C to a solution of LiAlH_4 (0.098 mol) in THF under N_2 . When the addition was complete, water (10ml) was added. The precipitate was filtered off and washed with CH_2Cl_2 . The organic layer was dried (MgSO_4), filtered off and evaporated. The product was used without further purification. Yield : 16.71g of 3-methyl-6-quinolinemethanol (interm. 17).
- c) MnO_2 (0.237 mol) was added to a solution of interm. 17 (0.096 mol) in CH_2Cl_2 (200ml) and the mixture was stirred at room temperature for 12 hours. The mixture was filtered through celite and the filtrate was stirred again with MnO_2 (20g) for 12 hours. MnO_2 (10g) was added again. The mixture was stirred for 12 hours. The mixture was filtered through celite and evaporated. The product was used without further purification. Yield : 11.71g of 3-methyl-6-quinolinecarboxaldehyde (71%) (interm. 18).
- d) A solution of bromocyclohexyl (0.14 mol) in 1,1'-oxybisethane (50ml) and Mg turnings (50ml) was added at 10°C to a mixture of THF (0.14 mol) in 1,1'-oxybisethane (10ml). A solution of interm. 18 (0.07 mol) in Mg turnings (100ml) was added carefully at 5°C, the mixture was poured into ice water and extracted with EtOAc. Yield : 11.34g of (\pm)- α -cyclohexyl-3-methyl-6-quinolinemethanol (63%) (interm. 19).

Example A10

Preparation of




(interm. 20)

- A mixture of compound (5) (0.001507 mol), tributyl(1-ethoxyethyl)stannane (0.00226 mol) and $\text{Pd}(\text{PPh}_3)_4$ (0.000151 mol) in 1,4-dioxane (5ml) was stirred at 80°C for 3 hours. Water was added. The mixture was extracted with EtOAc. The organic layer was separated, dried (MgSO_4), filtered and the solvent was evaporated. This product was used without further purification. Yield: 1.4g of interm. 20.

Example A11

Preparation of




(interm. 21)


- A mixture of compound (45) (prepared according to B6) (0.00125 mol) in NaOH 3N (5 ml) and iPrOH (1.7 ml) was stirred at room temperature overnight, then poured out into H_2O , acidified with HCl 3N and extracted with EtOAc. The organic layer was separated, dried (MgSO_4), filtered and the solvent was evaporated. The residue was taken up in diethyl ether. The precipitate was filtered off and dried. Yielding: 0.26 g of intermediate 23 (56%). (mp.: 232°C)

Example A12

a. Preparation of



(interm. 22)




(interm. 23)

- A mixture of 5-bromo-1H-indole-2,3-dione (0.221 mol) in NaOH 3N (500 ml) was stirred at 80°C for 30 minutes, brought to room temperature and 2-pentanone (0.221 mol) was added. The mixture was stirred and refluxed for 1 hour and 30 minutes and acidified with AcOH until pH=5. The precipitate was filtered, washed with water and dried. Yielding 52.3 g of intermediate 24 and intermediate 25. (Total yielding: 80%).

-35-

b. Preparation of




(interm. 24)

(interm. 25)

nBuLi 1.6 M (0.0816 mol) was added dropwise at -78°C to a suspension of intermediate 25 (0.034 mol) and intermediate 26 (0.034 mol) in THF (300 ml) under N_2 flow. The mixture was stirred at -78°C for 30 minutes. nBuLi 1.6M (0.0816 mol) was added dropwise. The mixture was stirred for 1 hour. A mixture of intermediate 9 (0.102 mol) in THF (250 ml) was added slowly. The mixture was stirred for -78°C to -20°C , poured out into $\text{H}_2\text{O}/\text{HCl}$ 3N and extracted with EtOAc. The organic layer was separated, dried (MgSO_4), filtered, and the solvent was evaporated till dryness. Yielding: 20.89 g of compound intermediate 26 and intermediate 27 (86%).

Example A13


a. Preparation of



(interm. 26)

4-amino-3-methoxybenzoic acid (0.054 mol) was added portionwise at room temperature to a solution of 3-chloro-2-ethyl-2-butenal (0.065 mol) in AcOH (100ml). The mixture was stirred and refluxed for 8 hours and evaporated to dryness. The residue was taken up in CH_2Cl_2 , water was added and the solution was basified by Et_3N . The organic layer was separated, dried (MgSO_4), filtered, and the solvent was evaporated. The residue was crystallized from 2-propanone. The precipitate was filtered off and dried. Yielding: 2.5g of interm. 26 (18%).

b. Preparation of




(interm. 27)

CDI (0.012 mol) was added at room temperature to a solution of interm. 26 (0.011 mol) in CH_2Cl_2 (30ml). The mixture was stirred at room temperature for 1 hour. methoxyaminomethyl (0.012 mol) was added and the mixture was stirred at room temperature for 8 hours. H_2O was added. A precipitate was filtered off. The filtrate was extracted with CH_2Cl_2 . The organic layer was separated, dried (MgSO_4), filtered, and

-36-

the solvent was evaporated. The residue was crystallized from diethyl ether. The precipitate was filtered off and dried. Yielding: 0.95g of interm. 27 (31%) (mp.:148°C).


Example A14

Preparation of (interm. 28)

- 5 4-Bromobenzenamine (0.034 mol) was added at room temperature to a solution of 3-chloride-2-ethyl-2-butanal (0.041 mol) in AcOH (60 ml). The mixture was stirred and refluxed for 8 hours, brought to room temperature and evaporated to dryness. The product was crystallized from EtOAc. The precipitate was filtered, washed with K₂CO₃ 10% and taken up in CH₂Cl₂. The organic layer was separated, dried
10 (MgSO₄), filtered, and the solvent was evaporated. Yielding: 4,6 g of interm. 28 (54%).

Example A15


a. Preparation of



(interm. 29)

- A solution of KOH (0.326 mol) in H₂O (150ml) was added slowly at 5°C to a solution of 1,3-cyclohexanedione (0.268 mol) in H₂O (150ml). The temperature must not reach
15 12 °C. KI (2g) then 2-bromo-1-(4-nitrophenyl)ethanone (0.294 mol) were added portionwise. The mixture was stirred at room temperature for 48 hours. The precipitate was filtered, washed with H₂O then with diethyl ether and dried. Yielding: 63g (85%). A part of this fraction (1g) was crystallized from EtOH. The precipitate was filtered off and dried. Yielding: 0.5g of interm. 29 (42%) (mp.: 100°C).

b. Preparation of




(interm. 30)

- 20 A mixture of interm. 29 (0.145 mol) in H₂SO₄ (40ml) was stirred at room temperature for 1 hour, poured out into ice, basified with NH₄OH and extracted with CH₂Cl₂. The organic layer was separated, dried (MgSO₄), filtered, and the solvent was evaporated. The residue was crystallized from EtOH. The precipitate was filtered off and dried. Yielding: 31g (58%). A part of this fraction (1g) was crystallized from EtOH. The
25 precipitate was filtered off and dried. Yielding: 0.7g of interm. 30 (58%) (mp.:200°C).

-37-


c. Preparation of



(interm. 31)

- A mixture of interm. 30 (0.039 mol), Raney Ni (10g) in EtOH (100ml) was hydrogenated at room temperature under a 3 bar pressure for 1 hour. The mixture was filtered over celite and washed with CH_2Cl_2 . The organic layer was separated, dried (MgSO_4), filtered, and the solvent was evaporated. The residue (9.5g) was crystallized from diethyl ether. The precipitate was filtered off and dried. Yielding: 4.6g (52%). The filtrate was evaporated. The residue (2.7g) was purified by column chromatography over silica gel (eluent: $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}$; 99/1; 15-40 μm). Two fractions were collected and the solvent was evaporated. Yielding: 1.6g F1 and 1.2g F2. F2 was crystallized from EtOH. The precipitate was filtered off and dried. Yielding: 0.24g of interm. 31 (2%) (mp.: 202°C).

d. Preparation of




(interm. 32)

- Interm. 30 (0.02 mol) was added at room temperature to a solution of 3-chloro-2-ethyl-2-butenal (0.04 mol) in AcOH (50ml). The mixture was stirred and refluxed for 4 hours. The solvent was evaporated till dryness. The residue was crystallized from EtOAc. The precipitate was filtered off and dried. The residue was taken up in CH_2Cl_2 . The mixture was basified with K_2CO_3 10% and extracted with CH_2Cl_2 . The organic layer was separated, dried (MgSO_4), filtered, and the solvent was evaporated. The residue was crystallized from EtOH. The precipitate was filtered off and dried. Yielding: 2.5g of interm. 32 (40%).

Example A16

Preparation of




(interm. 33)

- A mixture of 2-(4-nitrophenyl)-1-phenylethanone (0.083 mol) and Raney Ni (20g) in EtOH (200ml) was hydrogenated at room temperature for 1 hour under a 3 bar pressure, then filtered over celite, washed with $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}$ and dried. Yielding: 17.5g of interm. 33 (97%).

-38-

B. Preparation of the final compoundsExample B1

Preparation of




(compound 306)


- POCl₃ (0.024 mol) was added slowly at 5°C to DMF (0.024 mol). The mixture was stirred at room temperature for 30 minutes, then cooled to 5°C. 3-Oxo-butanoic acid ethyl ester (0.024 mol) was added slowly. The mixture was stirred at 5°C for 30 minutes. 1-(4-aminophenyl)-2-phenylethanone (0.024 mol) was added portionwise. The mixture was stirred at 90°C for 3 hours and dissolved in CH₂Cl₂. Ice water was added. The mixture was basified with NH₄OH and extracted with CH₂Cl₂. The organic layer was separated, dried (MgSO₄), filtered, and the solvent was evaporated. The residue was crystallized from 2-propanone/diethyl ether. The precipitate was filtered off and dried. Yielding: 0.9 g of compound 306 (11%) (mp.:136°C).

Example B2

Preparation of



(compound 2)


KMnO₄ (10g) was added portionwise at room temperature to a solution of

(prepared according to example A7.e) (0.022 mol)

- in tris(dioxo-3,6-heptyl)amine (1ml) and CH₂Cl₂ (100ml). The mixture was stirred at room temperature for 8 hours, filtered over celite, washed with CH₂Cl₂ and dried. The residue (6g, 100%) was crystallized from diethyl ether/petroleum ether. The precipitate was filtered off and dried. Yield: 2g of compound (2) (33%); mp. 82°C.

Example B3

a) Preparation of





(compound 3)

- nBuLi 1.6M (0.07 mol) was added slowly at -70°C to a solution of intermediate (5) (0.058 mol) in THF (150ml). The mixture was stirred at -70°C for 30 minutes. A solution of 2,3-dihydro-1H-Indene-2-carbonitrile (0.07 mol) in THF (100ml) was added slowly. The mixture was stirred at -70°C for 1 hour, brought slowly to room



temperature, hydrolyzed with H₂O and extracted with EtOAc. The organic layer was separated, dried (MgSO₄), filtered and the solvent was evaporated. The residue (22g) was purified by column chromatography over silica gel (eluent: CH₂Cl₂/cyclohexane 80/20 to 100; 15-35 μ m). The pure fractions were collected and the solvent was evaporated. The second fraction was crystallized from 2-propanone/diethyl ether. The precipitate was filtered off and dried. Yield: 0.11g of compound (3). The filtrate was concentrated. Yield: 0.55g of compound (3); mp. 145°C.

b) Preparation of



nBuLi 1.6M (0.022 mol) was added slowly at -70°C to a solution of intermediate (5) (0.018 mol) in THF (50ml). The mixture was stirred at -70°C for 1 hour, brought to -40°C, then cooled to -70°C. A solution of interm. 7 (0.018 mol) in THF (40ml) was added slowly. The mixture was stirred at -70°C for 1 hour, then brought to -20°C, hydrolyzed with H₂O and extracted with EtOAc. The organic layer was separated, dried (MgSO₄), filtered and the solvent was evaporated. The residue (6.5g) was purified by column chromatography over silica gel (eluent: toluene/EtOAc 90/10; 15-40 μ m). Two fractions (F1 and F2) were collected and the solvent was evaporated. F1 (2.4g) was crystallized from diethyl ether. The precipitate was filtered off and dried. Yield: 1.8g of compound (4) (29%); mp. 123°C. F2 (0.9g) was crystallized from diethyl ether. The precipitate was filtered off and dried. Yield: 0.2g of compound (5) (3%); mp. 120°C.


c) Preparation of



nBuLi 1.6M in exane (0.107 mol) was added dropwise at -78°C under N₂ flow to a mixture of intermediate (6) (0.089 mol) in THF. The mixture was stirred at -78°C for 1 hour. A mixture of interm. 7 (150 ml) was added at -78°C under N₂ flow. The mixture was stirred at -78°C for 2 hours, brought to 0°C, poured out into H₂O and extracted with EtOAc. The organic layer was separated, dried (MgSO₄), filtered and the solvent was evaporated. The residue (31g) was purified by column chromatography over silica gel (eluent: cyclohexane/EtOAc 85/15; 20-45 μ m). Two pure fractions were collected and their solvents were evaporated. Yielding: 11 g of compound (7) (38%) and 8.2 g of compound (8) (28%).

-40-

d) Preparation of




(compound 503)

A solution of chloromethylbenzene (0.0069 mol) in diethyl ether (8ml) was added slowly to a suspension of Mg (0.0069 mol) in a small amount of diethyl ether. The mixture was stirred at room temperature for 30 minutes (disparition of Mg), then cooled to 5°C. A solution of interm. 27 (0.0027 mol) in THF (8ml) was added slowly.

- 5 The mixture was stirred at 5°C for 15 minutes, then at room temperature for 2 hours, poured out into H₂O and filtered over celite. The precipitate was washed with EtOAc. The filtrate was extracted with EtOAc. The organic layer was separated, dried (MgSO₄), filtered, and the solvent was evaporated. The residue (1g) was purified by column chromatography over kromasil (eluent: CH₂Cl₂ 100 to CH₂Cl₂/CH₃OH 99/1;
- 10 15-40μm). The pure fractions were collected and the solvent was evaporated. The residue (0.5g, 56%) was crystallized from diethyl ether. The precipitate was filtered off and dried. Yielding: 0.14g of compound 503 (15%).


Example B4: examples of endgroup modifications

a) Preparation of



(compound 156)


A mixture of



(compound 8)


- 15 (prepared according to example B3.c) (0.018 mol) in HCl 3N (60ml) and THF (60ml) was stirred at 60°C overnight. The mixture was basified with a K₂CO₃ 10% solution and extracted with CH₂Cl₂. The organic layer was separated, dried (MgSO₄), filtered and the solvent was evaporated. Yield: 4.6g of compound (156) (82%).

b) Preparation of




(compound 9)


-41-



(prepared according to example B3.c) (0.0122 mol) in HCl 3N (40ml) and THF (40ml) was stirred and refluxed overnight, poured out into water, basified with K_2CO_3 10% and extracted with CH_2Cl_2 . The organic layer was separated, dried ($MgSO_4$), filtered and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent: cyclohexane/EtOAc 40/60; 15-40 μ m). The pure fractions were collected and the solvent was evaporated. Yield: 2g of compound (9) (52%); mp. 226°C.



A mixture of compound (4) (0.0015 mol), 2-methoxyethanamine (0.003 mol) and K_2CO_3 (0.003 mol) in DMF (5ml) was stirred at 140°C for 48 hours. H_2O was added. The mixture was extracted with EtOAc. The organic layer was separated, dried ($MgSO_4$), filtered and the solvent was evaporated. The residue (1g) was purified by column chromatography over silica gel (eluent: cyclohexane/EtOAc 60/40; 15-40 μ m). Two fractions were collected and the solvent was evaporated. Both fractions were crystallized separately from pentane. The precipitate was filtered off and dried. Yield: 0.05g of compound (10) (9%; mp. 115°C) and 0.057g of compound (11) (10%; mp. 107°C).




A mixture of compound (4) (0.0015 mol) in 2-(methylthio)ethanamine (2ml) was stirred at 120°C for 8 hours. K_2CO_3 10% was added. The mixture was extracted with CH_2Cl_2 . The organic layer was separated, dried ($MgSO_4$), filtered and the solvent was evaporated. The residue (2.2g) was purified by column chromatography over silica gel (eluent: cyclohexane/EtOAc 70/30; 15-40 μ m). Two fractions were collected and the solvent was evaporated. The first fraction was crystallized from diethyl ether/petroleum ether. The precipitate was filtered off and dried. Yield: 0.08g of compound (12) (14%); mp. 120°C. The second fraction was crystallized from diethyl

-42-

ether. The precipitate was filtered off and dried. Yield: 0.18g of compound (13) (31%); mp. 125°C.


e) Preparation of



cis (compound 14)

A mixture of compound (4) (0.001507 mol), ethynyltrimethylsilane (0.003013 mol), CuI (0.000151 mol) and Pd(PPh₃)₄ (0.000151 mol) in *N,N*-diethylethanamine (5ml) was stirred at 100°C for 24 hours. Water was added. The mixture was filtered over celite, washed with EtOAc and the filtrate was extracted with EtOAc. The organic layer was separated, dried (MgSO₄), filtered and the solvent was evaporated. The residue (1.3g) was purified by column chromatography over silica gel (eluent: cyclohexane/EtOAc 85/15; 15-40 μm). The pure fractions were collected and the solvent was evaporated. The residue (0.3g) was crystallized from pentane. The precipitate was filtered off and dried. Yield: 0.11g of compound (14) (18%); mp. 114°C.

f) Preparation of




(compound 15)


cis

A mixture of compound (14) (0.013 mol) and KF (0.038 mol) in acetic acid (50ml) was stirred at room temperature for 2 hours. H₂O was added and the mixture was extracted with diethyl ether. The organic layer was separated, dried (MgSO₄), filtered and the solvent was evaporated. The residue (4.4g) was purified by column chromatography over silica gel (eluent: cyclohexane/EtOAc 70/30; 15-40 μm). One fraction was collected and the solvent was evaporated. This fraction (3g, 73%) was crystallized from diethyl ether. The precipitate was filtered off and dried. Yield: 2.45g of compound (15) (60%); mp. 132°C.

g) Preparation of




cis (compound 15) and




trans (compound 17)

A mixture of



cis (compound 14) and



trans (compound 16)

-43-


prepared according to example B.7.a) (0.0056 mol) in KOH [1M, H₂O] (10ml) and methanol (30ml) was stirred at room temperature for 1 hour, poured out into water and extracted with EtOAc. The organic layer was separated, dried (MgSO₄), filtered and the solvent was evaporated. The residue (2.2g) was purified by column

5 chromatography over silica gel (eluent: cyclohexane/EtOAc 85/15 to 70/30; 15-40 μ m). Two fractions were collected and the solvent was evaporated.

The first fraction was crystallized from diethyl ether. The precipitate was filtered off and dried. Yield: 0.2g of compound (15) (11%); mp. 133°C.

10 The second fraction was crystallized from diethyl ether. The precipitate was filtered off and dried. Yield: 0.3g of compound (17) (16%); mp. 128°C.

h) Preparation of




(compound 18)

cis


A mixture of compound (4) (0.001205 mol), 2-propyn-1-ol (0.002411 mol), Pd(PPh₃)₄ (0.000121 mol) and CuI (0.000121 mol) in *N,N*-diethylethanamine (5ml) was stirred at 100°C for 2 hours. Water was added. The mixture was filtered over celite, washed with EtOAc and extracted with EtOAc. The organic layer was separated, dried
 15 (MgSO₄), filtered and the solvent was evaporated. The residue (0.7g) was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH 98/2; 15-40 μ m). The pure fractions were collected and the solvent was evaporated. The residue was crystallized from petroleum ether and diethyl ether. The precipitate was filtered off and dried. Yield: 0.1g of compound (18) (23%); mp. 113°C.

i) Preparation of



cis (compound 19)

and



(trans) (compound 20)


20 A mixture of compound (4) (0.006027 mol) and KF (0.024108 mol) in DMSO (20ml) was stirred at 140°C. The solvent was evaporated till dryness. The residue was solidified in water and diethyl ether. The mixture was extracted with diethyl ether. The organic layer was separated, washed with diethyl ether, washed with a saturated solution of NaCl, dried (MgSO₄), filtered and the solvent was evaporated. The residue
 25 (1.7g) was purified by column chromatography over silica gel (eluent: cyclohexane/EtOAc 85/15; 15-40 μ m). Three fractions were collected and their solvents were evaporated.

-44-

The first fraction was crystallized from petroleum ether. The precipitate was filtered off and dried. Yield: 0.21g of compound (19) (11%); mp. 92°C.

The second fraction was crystallized from petroleum ether. The precipitate was filtered off and dried. Yield: 0.33g of compound (20) (17%); mp. 114°C.

j) Preparation of




(compound 21)

cis

5 A mixture of compound (4) (0.003013 mol), acetyl chloride (0.003315 mol) and sodium iodide (0.006027 mol) in CH_3CN (10ml) was stirred and refluxed for 1 hour. K_2CO_3 10% was added. The mixture was extracted with CH_2Cl_2 . The organic layer was separated, dried (MgSO_4), filtered and the solvent was evaporated. The residue (1g) was purified by column chromatography over silica gel (eluent:

10 cyclohexane/EtOAc 80/20; 15-40 μm). Two fractions were collected and their solvents were evaporated. The first fraction was crystallized from petroleum ether. The precipitate was filtered off and dried. Yield: 0.12g of compound (21); mp. 110°C.

k) Preparation of




(compound 22)


cis

A mixture of compound (21) (0.000898 mol), trimethylsilanecarbonitrile (0.001347 mol) and $\text{Pd}(\text{PPh}_3)_4$ (0.00009 mol) in *N,N*-diethylethanamine (5ml) was stirred at 15 100°C for 2 hours. Water was added. The mixture was extracted with EtOAc. The organic layer was separated, dried (MgSO_4), filtered and the solvent was evaporated. The residue (0.4g) was purified by column chromatography over silica gel (eluent: cyclohexane/EtOAc 80/20; 15-40 μm). The pure fractions were collected and the solvent was evaporated. The residue (0.18g, 62%) was crystallized from petroleum 20 ether. The precipitate was filtered off and dried. Yield : 0.13g of compound (22) (45%); mp. 138°C.

l) Preparation of





cis (compound 23)




(trans) (compound 24)

-45-



- A mixture of compound (4) (0.00603 mol), $\text{Pd}(\text{OAc})_2$ (0.000603 mol), PPh_3 (0.00904 mol) and K_2CO_3 (0.012054 mol) in CO (gas) and methanol (40ml) was stirred at 90°C for 8 hours under a 5 bar pressure of CO. H_2O was added. The mixture was extracted with EtOAc. The organic layer was separated, dried (MgSO_4), filtered and the solvent was evaporated. The residue (6g) was purified by column chromatography over silica gel (eluent: $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}$ 100/0 to 98/2; 15-35 μm). Four fractions (F1-F4) were collected and the solvent was evaporated. Yield: 0.13g (cis) F1; 0.02g F2 (cis, compound 25); 0.055g F3 (trans, 3%) and 0.11g F4 (trans; compound 26). F1 was crystallized from petroleum ether. The precipitate was filtered off and dried. Yield: 0.03g of compound (23) (1%); mp. 91°C. F3 was crystallized from petroleum ether. The precipitate was filtered off and dried. Yield: 0.035g of compound (24) (1%); mp. 99°C.


m) Preparation of



(compound 25)

- A mixture of compound (4) (0.009 mol) and Zn (0.027 mol) in acetic acid (30ml) was stirred at 60°C for 4 hours, filtered over celite, washed with CH_2Cl_2 , evaporated till dryness, solubilized in CH_2Cl_2 and washed with K_2CO_3 10%. The organic layer was separated, dried (MgSO_4), filtered and the solvent was evaporated. The residue (4g) was purified by column chromatography over silica gel (eluent: cyclohexane/EtOAc 75/25; 15-40 μm). One fraction was collected and the solvent was evaporated. This fraction (1g 37%) was crystallized from petroleum ether. The precipitate was filtered off and dried. Yield: compound (25); mp. 88°C.

n) Preparation of




(compound 27)

- A mixture of compound (4) (0.001502 mol), $\text{Sn}(\text{CH}_3)_4$ (0.003004 mol) and $\text{Pd}(\text{PPh}_3)_4$ (0.00015 mol) in methylbenzene (5ml) was stirred and refluxed for 3 hours. K_2CO_3 10% was added. The mixture was extracted with EtOAc. The organic layer was separated, dried (MgSO_4), filtered and the solvent was evaporated. The residue (0.7g)

was purified by column chromatography over silica gel (eluent: cyclohexane/EtOAc 85/15; 15-40 μ m). Two fractions (F1 and F2) were collected and their solvents were evaporated. Yield: 0.27g (F1, starting material) and 0.14g (F2). F2 was crystallized from pentane and petroleum ether. The precipitate was filtered off and dried. Yield:

5 0.08g of compound (27) (17%); mp. 110°C.

o) Preparation of




(compound 28)

cis

A mixture of compound (4) (0.001507 mol), tributylethenylstannane (0.002260 mol) and Pd(PPh₃)₄ (0.000151 mol) in dioxane (5ml) was stirred at 80°C for 8 hours. Water was added. The mixture was filtered over celite, washed with EtOAc and extracted with EtOAc. The organic layer was separated, dried (MgSO₄), filtered and the solvent
10 was evaporated. The residue (0.65g) was purified by column chromatography over silica gel (eluent: cyclohexane/EtOAc 90/10; 15-40 μ m). The pure fractions were collected and the solvent was evaporated. The residue was crystallized from petroleum ether. The precipitate was filtered off and dried. Yield: 0.07g of compound (28) (14%); mp. 108°C.

p) Preparation of




(compound 29)

trans

A mixture of compound (5) (0.001507 mol), triphenyl(phenylmethyl)stannane (0.002260 mol) and Pd(PPh₃)₄ (0.000151 mol) in dioxane (5ml) was stirred at 80°C for 8 hours. Water was added. The mixture was extracted with EtOAc. The organic layer was separated, dried (MgSO₄), filtered and the solvent was evaporated. The residue (1.4g) was purified by column chromatography over silica gel (eluent: CH₂Cl₂/EtOAc
20 96/4; 15-40 μ m). The pure fractions were collected and the solvent was evaporated. The residue (0.38g) was crystallized from petroleum ether. The precipitate was filtered off and dried. Yield: 0.16g of compound (29) (28%); mp. 112°C.

q) Preparation of




(compound 30)

cis

-47-

- A mixture of compound (4) (0.001507 mol), tributyl-2-thienylstannane (0.00226 mol) and $\text{Pd}(\text{PPh}_3)_4$ (0.0001507 mol) in dioxane (5ml) was stirred at 80°C for 8 hours. K_2CO_3 10% was added. The mixture was extracted with EtOAc. The organic layer was separated, dried (MgSO_4), filtered and the solvent was evaporated. The residue (1.7g) was purified by column chromatography over silica gel (eluent: cyclohexane/EtOAc 85/15; 15-40 μm). The pure fractions were collected and the solvent was evaporated. The residue (0.65g) was crystallized from diethyl ether. The precipitate was filtered off and dried. Yield: 0.35g of compound (30) (61%); mp. 142°C.

r) Preparation of




(compound 31)

cis

- A mixture of compound (4) (0.0015 mol), 3-thienyl boronic acid (0.00226 mol), $\text{Pd}(\text{PPh}_3)_4$ (0.00015 mol) and dioxane was stirred and refluxed for 24 hours. K_2CO_3 10% was added. The mixture was extracted with EtOAc. The organic layer was separated, dried (MgSO_4), filtered and the solvent was evaporated. The residue (0.8g) was purified by column chromatography over silica gel (eluent: cyclohexane/EtOAc 80/20; 15-40 μm). The pure fractions were collected and the solvent was evaporated. The residue (0.4g, 70%) was crystallized from petroleum ether. The precipitate was filtered off and dried. Yield: 0.39g of compound (31) (68%); mp. 113°C.

s) Preparation of




(compound 32)


cis

- A mixture of compound (4) (0.003 mol), glycine methyl ester monohydrochloride (0.0066 mol) and $\text{Pd}(\text{PPh}_3)_4$ (0.0003 mol) in Et_3N (2ml) and toluene (10ml) was stirred at 100°C under 5 bar pressure of CO for 8 hours, filtered over celite, washed with CH_2Cl_2 and evaporated. The residue (2g) was purified by column chromatography over silica gel (eluent: cyclohexane/EtOAc 80/20; 75-35 μm). One fraction was collected and the solvent was evaporated. This fraction (1g 80%) was crystallized from diethyl ether. The precipitate was filtered off and dried. Yielding: 0.46g of compound (32) (37%).

t) Preparation of




cis (compound 33)



(trans) (compound 34)

- A mixture of compound (4) (0.003 mol) and hydrazinecarboxaldehyde (0.0045 mol) in 1-butanol (15ml) was stirred and refluxed overnight, poured out into water and extracted with CH_2Cl_2 . The organic layer was separated, dried (MgSO_4), filtered and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent: $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}/\text{NH}_4\text{OH}$ 95/5/0.1; 15-40 μm). Two fractions (F1 and F2) were collected and their solvents were evaporated. Yield: 0.3g F1 and 0.3g F2. F1 was crystallized from CH_3CN and diethyl ether. The precipitate was filtered off and dried. Yield: 0.102g of compound (33); mp. 224°C.
- F2 was crystallized from CH_3CN and diethyl ether. The precipitate was filtered off and dried. Yield: 0.2g of compound (34); mp. 185°C.

u) Preparation of




(compound 35)

cis


- A mixture of compound 4 (0.015 mol) and NaN_3 (0.045 mol) in DMF (50ml) was stirred at 140°C for 2 hours. K_2CO_3 10% was added and the mixture was extracted with EtOAc. The organic layer was separated, dried (MgSO_4), filtered and the solvent was evaporated. The residue (6g) was purified by column chromatography over silica gel (eluent: cyclohexane/EtOAc 60/40; 15-40 μm). The first fraction was collected and the solvent was evaporated. The residue was crystallized from diethyl ether. The precipitate was filtered off and dried. Yield: 1.26g of compound (35) (24%); mp. 160°C.

v) Preparation of



CIS

(compound 36)




TRANS

(compound 37)

- A mixture of compound (4) (0.009 mol) and thiourea (0.0099 mol) in ethyl alcohol (30ml) was stirred and refluxed for 12 hours and a solution of KOH (0.0149 mol) in H_2O (5ml) was added slowly. The mixture was stirred and refluxed for 1 hour, poured out into water and extracted with CH_2Cl_2 . The organic layer was separated, dried (MgSO_4), filtered and the solvent was evaporated. The residue was purified by column chromatography over silica gel (cyclohexane/EtOAc 70/30; 15-40 μm). The pure fractions were collected and the solvent was evaporated. Yielding: 1.1g of F1 (37%) and 0.4g of F2 (13%). F1 was crystallized from 2-propanone. The precipitate was


filtered off and dried. Yielding: compound (36). F2 was crystallized from 2-propanone. The precipitate was filtered off and dried. Yielding: compound (37).

w) Preparation of



cis

(compound 38)




TRANS

(compound 39)

- CH₃I (0.0034 mol) was added slowly at room temperature to a solution of compound (36) (0.0015 mol), compound (37) (0.0015 mol) and K₂CO₃ (0.0034 mol) in acetone (15ml). The mixture was stirred at room temperature for 8 hours. Water was added and the mixture was extracted with CH₂Cl₂. The organic layer was separated, dried (MgSO₄), filtered and the solvent was evaporated. The residue (1.2g) was purified by column chromatography over silica gel (eluent: cyclohexane/EtOAc 85/15; 15-40μm). The pure fractions were collected and the solvent was evaporated. Yielding: 0.6g F1 (57%), and 0.18g F2 (17%). F1 was crystallized from diethyl ether. The precipitate was filtered off and dried. Yielding: 0.28g compound (38) (27%). F2 was crystallized from diethyl ether. The precipitate was filtered off and dried. Yielding: 0.065g of compound (39) (6%).


x) Preparation of



cis

(compound 40)


A mixture of



compound (41) prepared

- according to example B3b (0.0014 mol) in HCl 3N (5ml) and THF (5ml) was stirred and refluxed for a weekend, then poured out into H₂O, basified with K₂CO₃ and extracted with CH₂Cl₂. The organic layer was separated, dried (MgSO₄), filtered and the solvent was evaporated. Yielding: 0.5g of F. This fraction F was crystallized from 2-propanone. The precipitate was filtered off and dried. Yielding: 0.35g of compound (40) (74%).


y) Preparation of



(compound 188)

- A mixture of compound (5) (0.045 mol), acetamide (0.90013 mol) and K_2CO_3 (0.225 mol) was stirred and refluxed at $200^\circ C$ for 2 hours, cooled at room temperature, poured out into H_2O/CH_2Cl_2 ; and extracted with CH_2Cl_2 . The organic layer was separated, dried ($MgSO_4$), filtered and the solvent was evaporated till dryness. The residue (14.4 g) was crystallized from CH_3OH . The precipitate was filtered off and dried. The filtrate was evaporated. The residue (11.27g) was purified by column chromatography over silica gel (eluent: $CH_2Cl_2/CH_3OH/NH_4OH$ 96/4/0.1; 15-35 μm). The pure fractions were collected and the solvent was evaporated. Yielding: 4.2 g of compound (188) (65%).


z) Preparation of



(compound 248)

- A mixture of compound (188) (0.00032 mol), benzoic acid (1.5 equiv., 0.00048 mol), 1-ethyl-3-(3'-dimethylaminopropyl)carbodiimide .HCl (1:1) (1.5 equiv., 0.00048 mol), N-hydroxybenzotriazole (1.5 equiv., 0.00048 mol) and Et_3N (1 equiv., 0.00032 mol) in CH_2Cl_2 (2ml) was stirred at room temperature for 15 hours. The solvent was evaporated. The residue was purified by HPLC and the product fractions were collected and the solvent was evaporated. Yield: 0.066 g of compound (205) (49.50%).

aa) Preparation of




(compound 6)

trans

- A mixture of interm. 20 (0.001507 mol) in HCl 3N (10ml) and THF (10ml) was stirred at room temperature for 8 hours, basified with K_2CO_3 10% and extracted with CH_2Cl_2 . The organic layer was separated, dried ($MgSO_4$), filtered and the solvent was evaporated. The residue (1.2g) was purified by column chromatography over silica gel (eluent: cyclohexane/EtOAc 85/15; 15-40 μm). The pure fractions were collected and the solvent was evaporated. The residue (0.4g) was crystallized from petroleum ether. The precipitate was filtered off and dried. Yield: 0.3g of compound (6) (58%); mp. $108^\circ C$.

-51-

ab) Preparation of




(compound 419)


- A mixture of compound 213 (prepared according to B4) (0.00305 mol) and CH_3ONa (30% in CH_3OH) (0.00916 mol) in CH_3OH (25ml) was stirred and refluxed for 15 hours then cooled to room temperature, poured out into H_2O and extracted with EtOAc . The organic layer was separated, dried (MgSO_4), filtered, and the solvent was
- 5 evaporated till dryness. The residue (1.1g) was purified by column chromatography over silica gel (eluent: cyclohexane/ EtOAc ; 40/60; 15–40 μm). Two fractions were collected and the solvent was evaporated. Yielding: 0.3g F1 and 0.5g F2 (50%) F2 was crystallized from diethyl ether/petroleum ether. The precipitate was filtered off and dried. Yielding: 0.26g F1 was crystallized from pentane. The precipitate was filtered
- 10 off and dried. Yielding: 0.19g. This fraction was purified by column chromatography over silica gel (eluent: $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}$; 98/2; 15–40 μm). The pure fractions were collected and the solvent was evaporated. Yielding: 0.11g. This fraction was purified by column chromatography over kromasil (eluent: $\text{CH}_3\text{OH}/\text{H}_2\text{O}$; 70/30). The pure
- 15 fractions were collected and the solvent was evaporated. Yielding: 0.09g. (9%) This fraction was crystallized from diethyl ether. The precipitate was filtered off and dried. Yielding: 0.08g of compound 419 (8%).

Example B5

Preparation of



cis (compound 42)




(trans) (compound 43)

- Iodomethane (0.00456 mol) was added at 5°C to a mixture of compound (9) (0.0019 mol), compound (8) (0.0019 mol) and tBuOK (0.00456 mol) in THF (30ml) under N_2
- 20 flow. The mixture was stirred at room temperature overnight, poured out into H_2O and extracted with CH_2Cl_2 . The organic layer was separated, dried (MgSO_4), filtered and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent: cyclohexane/ EtOAc 65/35; 15–40 μm). Two fractions were collected and the solvent was evaporated. Yield: 0.35g of compound (42) (30%; mp. 125°C) and
- 25 0.35g of compound (43) (30%; mp. 116°C).


-52-

Example B6

a) Preparation of



cis (compound 44)




(trans) (compound 45)

NaH 60% (0.01068 mol) was added at 0°C under N₂ flow to a mixture of compound (8) and compound (9) (0.0089 mol). The mixture was stirred for 30 minutes.


- 5 Ethyl bromoacetate (0.01068 mol) was added at 0°C. The mixture was stirred at room temperature for 1 hour, hydrolyzed with water and extracted with EtOAc. The organic layer was separated, dried (MgSO₄), filtered and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent: cyclohexane/EtOAc 60/40; 15-40 μm). The desired fractions (F1-F4) were collected and the solvent was evaporated. Yield: 0.11g F1; 0.13g F2; 0.75g F3 and 0.8g F4.
- 10 F3 was crystallized from diethyl ether. The precipitate was filtered off and dried. Yield: compound (44); mp. 152°C.

F4 was crystallized from diethyl ether. The precipitate was filtered off and dried. Yield: compound (45); mp. 147°C.

b) Preparation of



cis (compound 46)



(trans) (compound 47)



- Bromomethylbenzene (0.007 mol) was added dropwise at 0°C under N₂ flow to a solution of compound (8) and compound (9) (0.0064 mol) and NaH 60% (0.007 mol) in DMF (40ml). The mixture was stirred at room temperature for 1 hour, hydrolyzed with water and extracted with EtOAc. The organic layer was separated, washed with water, dried (MgSO₄), filtered and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent: cyclohexane/EtOAc 70/30; 15-40 μm).
- 20 The desired fractions (F1-F4) were collected and the solvent was evaporated. Yield: 0.15g F1, 0.1g F2, 0.6g F3 (23%) and 0.8g F4.
- F3 was crystallized from diethyl ether. The precipitate was filtered off and dried. Yield: 0.13g of compound (46); mp. 137°C.
- F4 was crystallized from DIPE and petroleum ether. The precipitate was filtered off and dried. Yield: compound (47); mp. 130°C.
- 25

Example B7

- a) 3-Chlorobenzenecarboxylic acid (0.088 mol) was added at 0°C to a solution of compound (48) (prepared according to example B2) (0.044 mol) in CH₂Cl₂ (200ml) and the mixture was stirred at room temperature for 12 hours. The mixture was washed with K₂CO₃ 10%. The organic layer was dried (MgSO₄), filtered off and evaporated. The residue was recrystallized from (C₂H₅)₂O. Yield : 8.2g of cyclohexyl(3-methyl-6-quinolinyl)methanone,1-oxide (compound 49) (69%).
- b) 4-Methyl benzenesulfonyl chloride (0.043 mol) was added to a solution of compound (49) (0.028 mol) in K₂CO₃ (400ml) and CH₂Cl₂ (400ml) and the mixture was stirred at room temperature for 1 hour. The mixture was extracted with CH₂Cl₂. The organic layer was dried (MgSO₄), filtered off and evaporated. The residue was recrystallized from (C₂H₅)₂O. Yield : 6.64g of 6-(cyclohexylcarbonyl)-3-methyl-2(1H)-quinolinone (compound 50) (85%); mp. 256.1°C.


15 Example B8

a) Preparation of



- A mixture of compound (7) (0.0229 mol), hydroxylamine (0.0252 mol) and *N,N*-diethylethanamine (0.0252 mol) in ethanol (100ml) was stirred and refluxed for 6 hours, poured out into water and extracted with CH₂Cl₂. The organic layer was separated, dried (MgSO₄), filtered and the solvent was evaporated. The residue was crystallized from CH₃CN. The precipitate was filtered off and dried. The residue was purified by column chromatography over silica gel (eluent: CH₂Cl₂/EtOAc 80/20; 15-40μm). Two fractions were collected and the solvent was evaporated. Yielding: 2.8g of compound (44) (36%; mp. 133°C) and 3g of compound (45) (38%; mp. 142°C).

b) Preparation of



(compound 53)


- Hydrazine (0.41 mol) was added at room temperature to a solution of compound (7) (0.015 mol) in ethanol (75ml). The mixture was stirred and refluxed for 1 night, poured out into water and extracted with CH₂Cl₂. The organic layer was separated, dried (MgSO₄), filtered and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH/NH₄OH 98/2/0.1).

-54-

The pure fractions were collected and the solvent was evaporated. The residue was crystallized from diethyl ether. The precipitate was filtered off and dried. Yielding: 0.8g of compound (53) (15%); mp. 110°C.

Example B9

Preparation of




(compound 520)

- 5 Procedure for compounds 400, 401, 402, 403, 404 and 405. A mixture of interm. 21 (prepared according to A11) (0.000269 mol), amantadine hydrochloride (0.000404 mol; 1.5 eq.), *N'*-(ethylcarbonimidoyl)-*N,N*-dimethyl-1,3-propanediamine hydrochloride (0.000404 mol; 1.5 equiv.), 1-hydroxy-1*H*-benzotriazole (0.000404 mol; 1.5 equiv.) and Et₃N (0.000269 mol) in CH₂Cl₃ (2 ml) was stirred at room temperature
- 10 for 12 hours. The solvent was evaporated. The residue was purified by HPLC. The product fractions were collected and the solvent was evaporated. Yield: 0.063 g of compound 520 (46.37%).

Example B10

Preparation of




(compound 233)

- A mixture of intermediate 27 (0.0026 mol) and intermediate 26 (0.0026 mol) in EtOH (380 ml) and H₂SO₄ conc. (19 ml) was stirred and refluxed for 15 hours, the cooled to room temperature, poured out into ice water, basified with K₂CO₃ and extracted with EtOAc. The organic layer was separated, dried (MgSO₄), filtered, and the solvent was evaporated. The residue (17.9 g) was purified by column chromatography over silica gel (eluent: cyclohexane/EtOAc; 80/20; 15-35μm). The pure fractions were collected
- 20 and the solvent was evaporated. Yielding: 0.85 g of F1, 1.1 g F2 and 11.5 g of F3. F1 and F2 were crystallized separately from petroleum ether. The precipitate was filtered off and dried. Yielding: 0.34 g of compound 233.

Example B11

Preparation of




(compound 511)

- A mixture of compound 22 (prepared according to B4) (0.004 mol) in HCl (3N) (20ml) and THF (20ml) was stirred and refluxed for 8 hours, poured out on ice, basified with NH_4OH and extracted with CH_2Cl_2 . The organic layer was separated, dried (MgSO_4), filtered, and the solvent was evaporated. The residue (1.2g) was purified by column chromatography over silica gel (eluent: $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}/\text{NH}_4\text{OH}$; 93/7/0.5; 15–40 μm). Two fractions were collected and the solvent was evaporated. Yielding: 0.5g F1 (41%) and 0.4g of F2. F1 was crystallized from petroleum ether. The precipitate was filtered off and dried. Yielding: 0.17g of compound 511 (14%).

10 Example B12

Preparation of




(compound 514)

- A mixture of compound 524 (prepared according to B9a) (0.0018 mol) and KOH 85% (0.0094 mol) in EtOH (15ml) was stirred and refluxed for 24 hours, poured out into H_2O and extracted with CH_2Cl_2 . The organic layer was separated, dried (MgSO_4), filtered, and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent: $\text{CH}_2\text{Cl}_2/\text{Cyclohexane}$ 80/20; 15–40 μm). Two fractions were collected and the solvent was evaporated. Yielding: 0.35g F1 (64%) and 0.17g (SM) F1 was crystallized from diethyl ether. The precipitate was filtered off and dried. Yielding: 0.33g of compound 514 (60%) (mp.:185°C).

Example B13

Preparation of



(compound 515)


- A mixture of interm. 28 (0.019 mol), 2-benzofuranylboronic acid (0.028 mol), $\text{Pd}(\text{PPh}_3)_4$ (0.001 mol) and BHT (a few quantity) in dioxane (25ml) and Na_2CO_3 [2] (25ml) was stirred and refluxed for 8 hours and extracted with EtOAc. The aqueous layer was basified with NH_4OH and extracted with CH_2Cl_2 . The organic layer was separated, dried (MgSO_4), filtered, and the solvent was evaporated. The residue (3.6g) was purified by column chromatography over silica gel (eluent: $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}$ 99/1;

-56-

15-40 μ m). The pure fractions were collected and the solvent was evaporated. Yielding: 1.8g (33%). This fraction was crystallized from 2-propanone/diethyl ether. The precipitate was filtered off and dried. Yielding: 0.39g of compound 515 (7%) (mp.:134°C).

5 Example B14

Preparation of




(compound 526)

Triethylsilane (0.0012 mol) was added slowly at room temperature to a solution of interm. 32 (0.004 mol) in CF₃COOH (5ml) and AcOH (10ml). NaBH₄ (0.0012 mol) was added portionwise under N₂ flow. The mixture was stirred at room temperature for 8 hours, poured out on ice, basified with K₂CO₃ and extracted with CH₂Cl₂. The organic layer was separated, dried (MgSO₄), filtered, and the solvent was evaporated. The residue (1.2g) was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH 99/1; 15-40 μ m). Two fractions were collected and the solvent was evaporated. Yielding: 0.5g F1 (43%) and 0.4g F2. F1 was dissolved in iPrOH. HCl/iPrOH (1 eq) were added. The precipitate was filtered off and dried; Yielding: 0.32g of compound 526 (mp.: 248°C).

15 Example B15

Preparation of




(compound 471)












A mixture of interm. 33 (0.082 mol) and 3-chloro-2-ethyl-2-butenal (0.098 mol) in AcOH (200ml) was stirred and refluxed for 8 hours. The solvent was evaporated till dryness. The residue was dissolved in CH₂Cl₂ and washed with K₂CO₃ 10%. The organic layer was separated, dried (MgSO₄), filtered, and the solvent was evaporated. The residue (27g) was purified by column chromatography over silica gel (eluent: CH₂Cl₂/EtOAc 95/5 to 92/8; 15-35 μ m). Two fractions were collected and the solvent was evaporated. Yielding: 0.7g of F1 and 5.3g F2. F1 was crystallized from 2-propanone/diethyl ether. The precipitate was filtered off and dried. Yielding: 0.25g of compound 471 (2%) (mp.: 140°C).







Tables 1 to 8 list the compounds of formula (I-A) and (I-B) which were prepared according to one of the above examples.














Table 1


















Có. no.	Ex. no.	R ²	R ³	R ⁴	R ¹	physical data
54	B2	Cl	ethyl	H		-
3	B3a	Cl	ethyl	H		mp. 145°C
55	B3b	Cl	ethyl	H		mp. 131°C
56	B3b	Cl	ethyl	H		mp. 104°C
57	B3b	Cl	ethyl	H	phenylethyl	mp. 100°C
58	B3b	Cl	ethyl	H		mp. 126°C
59	B3b	Cl	ethyl	H		mp. 150°C
60	B3b	Cl	ethyl	H		mp. 138°C
61	B3b	OCH ₃	ethyl	H		-
62	B3b	OCH ₃	ethyl	H		mp. 130°C
63	B3b	OCH ₃	ethyl	H		mp. 116°C
64	B3b	Cl	ethyl	H	-(CH ₂) ₂ -O-CH ₃	mp. 82°C
65	B3b	OCH ₃	ethyl	H	1-methylcyclohexyl	mp. 82°C
66	B3b	OCH ₃	ethyl	H	3-methoxycyclohexyl	trans; mp. 94°C
67	B3b	OCH ₃	ethyl	H	3-methoxycyclohexyl	cis; mp. 108°C















Co. no.	Ex. no.	R ²	R ³	R ⁴	R ¹	physical data
68	B3b	OCH ₃	ethyl	H	4-(methylethoxy)-cyclohexyl	(A), mp. 82°C
69	B3b	OCH ₃	ethyl	H	4-[C(CH ₃) ₃]cyclohexyl	cis; mp. 92°C
70	B3b	OCH ₃	ethyl	H	4-[C(CH ₃) ₃]cyclohexyl	trans; mp. 108°C
71	B3b	OCH ₃	ethyl	H	4-methylcyclohexyl	(B), mp. 92°C
72	B3b	OCH ₃	ethyl	H	4-methylcyclohexyl	(A), mp. 80°C
2	B2	Cl	ethyl	H	CH ₂ -CH(CH ₃) ₂	mp. 82°C
73	B3b	Cl	ethyl	H	-CH ₂ -O-C ₂ H ₅	mp. 82°C
48	B2	H	methyl	H	cyclohexyl	-
74	B4	I	ethyl	H		-
75	B4	I	ethyl	H		mp. 124°C
76	B4	I	ethyl	H		mp. 138°C
77	B4	I	ethyl	H		mp. 120°C
78	B4	CN	ethyl	H		mp. 128°C
79	B4	CN	ethyl	H		mp. 136°C
80	B4	CN	ethyl	H		mp. 120°C
81	B4	CN	ethyl	H		mp. 139°C
82	B4	methyl	ethyl	H		mp. 106°C
83	B4	methyl	ethyl	H		mp. 149°C
84	B4	methyl	ethyl	H		mp. 118°C














Co. no.	Ex. no.	R ²	R ³	R ⁴	R ¹	physical data
85	B4	methyl	ethyl	H		mp. 180°C
86	B4	methyl	ethyl	H	phenylethyl	mp. 53°C
87	B4	methyl	ethyl	H		mp. 87°C
88	B4	methyl	ethyl	H	-CH ₂ -CH(CH ₃) ₂	mp. 68°C
89	B4	methyl	ethyl	H		mp. 120°C
31	B4	3-thiazolyl	ethyl	H	4-methoxycyclohexyl	cis; 113°C
90	B3b	OCH ₃	H	H	4-methoxycyclohexyl	trans, mp. 126°C
91	B3b	OCH ₃	H	H	4-methoxycyclohexyl	cis, mp. 100°C
92	B3b	OCH ₃	H	CH ₃	4-methoxycyclohexyl	cis; mp. 120°C
93	B3b	OCH ₃	H	CH ₃	4-methoxycyclohexyl	trans; mp. 111°C
94	B3b	OCH ₃	methyl	H	4-methoxycyclohexyl	cis, mp. 96°C
95	B3b	OCH ₃	phenyl	H	4-methoxycyclohexyl	cis; HCl (1:1), mp. 138°C
96	B3b	OCH ₃	propyl	H	4-methoxycyclohexyl	trans; mp. 118°C
97	B3b	OCH ₃	propyl	H	4-methoxycyclohexyl	cis; mp. 108°C
98	B3b	OCH ₃	methyl	H	4-methoxycyclohexyl	cis; mp. 104°C
99	B4	N(CH ₃) ₂	ethyl	H		(B); mp. 102°C
100	B3b	Cl	ethyl	H		mp. 114°C
101	B4	methyl	ethyl	H	4-butoxycyclohexyl	cis; mp. 86°C
102	B3b	Cl	ethyl	H		mp. 78°C














Co. no.	Ex. no.	R ²	R ³	R ⁴	R ¹	physical data
103	B3b	Cl	ethyl	H		mp. 91°C
104	B4	N(CH ₃) ₂	ethyl	H		mp. 103°C
105	B4	N(CH ₃) ₂	ethyl	H		mp. 170°C
106	B3b	Cl	ethyl	H		mp. 137°C
107	B3b	Cl	ethyl	H		mp. 137°C
108	B4	methyl	ethyl	ethyl	4-methoxycyclohexyl	cis; mp. 91°C
109	B4	methyl	ethyl	H	4-ethoxycyclohexyl	trans; mp. 150°C
110	B4	methyl	ethyl	H		mp. 90°C
111	B4	methyl	ethyl	H		mp. 94°C
112	B4	methyl	ethyl	H		mp. 176°C
113	B4	methyl	ethyl	H		mp. 106°C
114	B4	propyl	H	H	4-methoxycyclohexyl	cis; mp. 74°C
115	B4	methyl	ethyl	H	4-ethoxycyclohexyl	cis; mp. 108°C
116	B4	methyl	ethyl	H		mp. 110°C
117	B3b	Cl	ethyl	H		mp. 124°C
118	B3b	Cl	ethyl	H		mp. 107°C
119	B3b	Cl	ethyl	H		mp. 129°C














Co. no.	Ex. no.	R ²	R ³	R ⁴	R ¹	physical data
120	B4	methyl	ethyl	H		mp. 106°C
41	B3b	Cl	ethyl	H		trans; mp. 157°C
182	B3b	methyl	ethyl	H		cis; mp. 170°C
183	B3b	methyl	ethyl	H		trans; mp. 144°C
184	B3b	methyl	ethyl	H		mp. 138°C
185	B3b	Cl	ethyl	H		mp. 120°C
186	B3b	Cl	ethyl	H		
187	B3b	methyl	ethyl	H		mp. 162°C
216	B4	CC≡N	ethyl	H		mp.:160°C
217	B4	methyl	ethyl	H		ethanedioate (1:1); mp.:143°C
218	B4	I	ethyl	H		mp.:102°C
219	B4	CC≡N	ethyl	H		mp.:115°C
220	B4	Cl	ethyl	H		(A); mp.:107°C
221	B4	Cl	ethyl	H		(B); mp.:113°C
222	B4	I	ethyl	H		mp.:206°C

















Co. no.	Ex. no.	R ²	R ³	R ⁴	R ¹	physical data
223	B4	Cl	ethyl	H		(trans); mp.:117°C
224	B4	methyl	ethyl	H		(A); mp.:103°C
225	B2	Cl	ethyl	H		mp.:94°C
226	B3b	Cl	ethyl	H		(trans); mp.:157°C
227	B3c	methoxy		H		mp.:204°C
228	B4	Cl	ethyl	H		(A); mp.:136°C
229	B3b	n-propyl	H	H		(trans); HCl (1:1); mp.:150°C
230	B3b	Cl	ethyl	H		mp.:116°C
231	B3b	Cl	ethyl	H		mp.:120°C
232	B3b	Cl	ethyl	H		mp.:112°C
233	B10	i-propyl	H	C(=O)O-C ₂ H ₅		(cis); mp.:91°C
234	B4	methyl	ethyl	H		mp.:122°C
235	B4	methyl	ethyl	H		mp.:106°C

















Co. no.	Ex. no.	R ²	R ³	R ⁴	R ¹	physical data
236	B4	methyl	ethyl	H		mp.:104°C
237	B4	methyl	ethyl	H		mp.:90°C
238	B4	methyl	H	H		(cis); mp.:80°C
239	B3b	Cl	ethyl	H		(trans); mp.:126°C
240	B3b	Cl	ethyl	H		(cis); mp.:128°C
241	B4	methyl	ethyl	H		(A); mp.:90°C
242	B4	methyl	ethyl	H		(B); mp.:110°C
243	B3b	Cl	ethyl	H		mp.:134°C
244	B3b	Cl	ethyl	H		mp.:127°C
245	B4	NHC(=O)NH ₂	ethyl	H		(cis); mp.:176°C
246	B4	methyl	ethyl	H		(B)
247	B3b	Cl	ethyl	H		mp.:92°C
248	B4	methyl	ethyl	H		(A); mp.:80°C
249	B3b	Cl	ethyl	H		(B); mp.:138°C

Co. no.	Ex. no.	R ²	R ³	R ⁴	R ¹	physical data
250	B4	methyl	ethyl	H	 O-npropyl	(trans); mp.:118°C
251	B4	methyl	ethyl	H		(B);.HCl(1:1)
252	B3b	Cl	ethyl	H	 isopropyl	(A)
253	B3b	Cl	ethyl	H	 isopropyl	(B)
254	B3b	methyl	ethyl	H	 (CH ₂) ₄	mp.:74°C
255	B4	methyl	ethyl	H	 O-npropyl	(cis); mp.:68°C
256	B4	methyl	ethyl	H	 HO	mp.:210°C
257	B4	methyl	ethyl	H	 OCH ₃	mp.:113°C
258	B4	methyl	ethyl	H	 C ₂ H ₅ CH ₃	mp.:92°C
259	B3b	methyl	ethyl	H	 OCH ₃	mp.:115°C
260	B3b	methyl	ethyl	H	 OCH ₃	mp.:60°C
261	B3b	Cl	ethyl	H	 C ₂ H ₅	(A); mp.:86°C
262	B3b	Cl	ethyl	H	 C ₂ H ₅	(B); mp.:101°C

Co. no.	Ex. no.	R ²	R ³	R ⁴	R ¹	physical data
263	B3b	methyl	ethyl	H		mp.:130°C
264	B3b	Cl	ethyl	H		(A); mp.:124°C
265	B3b	Cl	ethyl	H		(B); mp.:126°C
266	B4	N(CH ₃) ₂	ethyl	H		(trans); mp.:102°C
267	B4	N(CH ₃) ₂	ethyl	H		(cis);.HCl(1:1); mp.:170°C
268	B4	methyl	ethyl	H		(A);.HCl(1:1); mp.:206°C
269	B4	methyl	ethyl	H		mp.:104°C
270	B3b	methyl	ethyl	H		mp.:117°C
271	B4	NHC ₂ H ₅ OCH ₃	ethyl	H		-
272	B4	methyl	ethyl	H		-
273	B4	NH ₂	ethyl	H		-
274	B3b	Cl	ethyl	H		-
275	B3b	Cl	ethyl	H		mp.:99°C

Co. no.	Ex. no.	R ²	R ³	R ⁴	R ¹	physical data
276	B3b	Cl	ethyl	H		mp.:95°C
277	B4	methyl	ethyl	H		mp.:105°C
278	B3b	Cl	ethyl	H		mp.:141°C
279	B4	Cl	ethyl	H		mp.:168°C
280	B4	Cl	ethyl	H		-
281	B4	Cl	ethyl	H		mp.:140°C
282	B4	Cl	ethyl	H		mp.:169°C
283	B4	methyl	ethyl	H		mp.:96°C
284	B3b	Cl	CH ₂ N(CH ₃) ₂	H		mp.:115°C
285	B4	methyl	ethyl	H		mp.:133°C
286	B4	methyl	CH ₂ OCH ₃	H		(trans); mp.:106°C
287	B4	methyl	CH ₂ N(CH ₃) ₂	H		(cis); mp.:110°C
288	B3b	Cl	<i>n</i> -propyl	H		mp.:110°C

Co. no.	Ex. no.	R ²	R ³	R ⁴	R ¹	physical data
289	B4	NH ₂	ethyl	H		mp.:218°C
290	B4	methyl	<i>n</i> -propyl	H		mp.:90°C
291	B3b	Cl	<i>n</i> -propyl	H		(cis); mp.:128°C
292	B3b	Cl	<i>n</i> -propyl	H		(trans); mp.:104°C
293	B3b	Cl	ethyl	H		mp.:106°C
294	B4	methyl	<i>n</i> -propyl	H		(cis); mp.:94°C
295	B4	methyl	CH ₂ N(CH ₃) ₂	H		mp.:83°C
296	B3b	Cl	ethyl	H		mp.:99°C
297	B3b	Cl	ethyl	H		mp.:110°C
298	B4	methyl	ethyl	H		mp.:93°C
299	B4	methyl	ethyl	H		mp.:105°C
300	B4	methyl	ethyl	H		mp.:114°C
301	B3b	methyl	ethyl	H		mp.:143°C
302	B4	methoxy	ethyl	H		mp.:93°C
303	B4	methyl	ethyl	H		mp.:82°C
304	B4	<i>n</i> -butyl	ethyl	H		-

Co. no.	Ex. no.	R ²	R ³	R ⁴	R ¹	physical data
305	B3b	Cl	n-propyl	H		mp.:125°C
306	B1	methyl	C(=O)OC ₂ H ₅	H		mp.:136°C
307	B4	methyl	n-propyl	H		mp.:81°C
308	B4	methoxy	n-propyl	H		mp.:80°C
309	B4	I	n-propyl	H		mp.:120°C
310	B3d	methyl	ethyl	H		.HCl(1:1); mp.:129°C
311	B3b	Cl	H	H		mp.:160°C
312	B3b	Cl	H	H		(trans); mp.:145°C
313	B3b	Cl	H	H		mp.:103°C
314	B4	n-propyl	n-propyl	H		.HCl(1:1); mp.:150°C
315	B4	n-propyl	ethyl	H		.HCl(1:1)
316	B4	n-propyl	H	H		.HCl(1:1); mp.:140°C
317	B3b	Cl	H	H		mp.:168°C
318	B4	methyl	n-propyl	H		.HCl(1:1); mp.:200°C
509	B3b	Cl	ethyl	H		-
510	B4	methyl	ethyl	H		.H ₂ O(1:1)



















Co. no.	Ex. no.	R ²	R ³	R ⁴	R ¹	physical data
513	B4	methyl	ethyl	H		-
516	B4	Cl	ethyl	H		mp.: 120°C
517	B4	I	ethyl	H	CH ₂ CH(CH ₃) ₂	-
518	B4	Cl	ethyl	H		-
519	B4	Cl	ethyl	H		(A+B)
521	B4	I	ethyl	H		-
522	B4	methyl	ethyl	H		(A)
1	B4	methyl	ethyl	H		(A)
525	B4	Cl	ethyl	H		-
527	B4	F	ethyl	H		mp.: 116°C













Table 2



Co. no.	Ex. no.	R ²	X	physical data
5	B3b	Cl	O	trans; mp. 120°C
121	B3b	1-piperidinyl	O	cis; HCl (1:1)
122	B3b	1-piperidinyl	O	trans; HCl (1:1); mp. 128°C
123	B3b	4-thiomorpholinyl	O	cis; mp. 105°C
124	B3b	4-thiomorpholinyl	O	trans; mp. 115°C














Co. no.	Ex. no.	R ²	X	physical data
125	B3b	4-morpholinyl	O	trans; mp. 118°C
126	B3b	4-morpholinyl	O	cis; mp. 118°C
127	B3b	-N(CH ₃) ₂	O	trans; mp. 96°C
128	B3b	-N(CH ₃) ₂	O	cis; mp. 114°C
4	B3b	Cl	O	cis; mp. 123°C
8	B3c	OCH ₃	O	trans, mp. 68°C
7	B3c	OCH ₃	O	cis, mp. 116°C
6	B4	acetyl	O	trans; mp. 108°C
129	B4	acetyl	O	cis; mp. 106°C
11	B4	NH-(CH ₂) ₂ -OCH ₃	O	trans; mp. 107°C
10	B4	NH-(CH ₂) ₂ -OCH ₃	O	cis; mp. 115°C
12	B4	NH-(CH ₂) ₂ -SCH ₃	O	cis; mp. 120°C
13	B4	NH-(CH ₂) ₂ -SCH ₃	O	trans; mp. 125°C
14	B4	-C≡C-Si(CH ₃) ₃	O	cis; mp. 114°C
16	B4	-C≡C-Si(CH ₃) ₃	O	trans; mp. 108°C
15	B4	-C≡CH	O	cis; mp. 132-133°C
17	B4	-C≡CH	O	trans; mp. 128°C
18	B4	-C≡C-CH ₂ OH	O	cis; mp. 113°C
130	B4	-C≡C-CH ₂ OH	O	trans; mp. 108°C
19	B4	F	O	cis; mp. 92-99°C
20	B4	F	O	trans; mp. 114°C
21	B4	I	O	cis; mp. 110°C
22	B4	CN	O	cis; mp. 137-138°C
26	B4	H	O	trans
23	B4	-C(=O)-OCH ₃	O	cis; mp. 91°C
24	B4	-C(=O)-OCH ₃	O	trans; mp. 99°C
25	B4	H	O	cis; mp. 88°C
27	B4	methyl	O	cis; mp. 110-112°C
131	B4	methyl	O	trans; mp. 25°C
28	B4	ethenyl	O	cis; mp. 108°C
132	B4	ethenyl	O	trans; mp. 103°C
29	B4	phenyl	O	trans; mp. 112°C
30	B4	2-thienyl	O	cis; 142°C
133	B4	2-thiazolyl	O	cis; 108°C

Co. no.	Ex. no.	R ²	X	physical data
134	B4	2-furanyl	O	cis; mp. 105°C
51	B8a	OCH ₃	N-OH	[1α(A),4α]; mp. 133°C
52	B8a	OCH ₃	N-OH	[1α(B),4α]; mp. 142°C
53	B8b	OCH ₃	NNH ₂	[1α(Z),4α]; mp. 110°C
135	B4	NH ₂	O	cis; mp. 203°C
136	B4	NH ₂	O	trans; mp. 202°C
137	B4	-C(=O)-OCH(CH ₃) ₂	O	cis; mp. 105°C
138	B4	-C(=O)-OCH(CH ₃) ₂	O	trans; mp. 88°C
38	B4	SCH ₃	O	cis; mp. 124°C
39	B4	SCH ₃	O	trans; mp. 116°C
32	B4		O	cis; mp. 130°C
139	B4	ethyl	O	cis; mp. 180°C
188	B4	NH ₂	O	cis + trans
189	B4		O	cis; mp. 154°C
190	B4		O	trans; mp. 156°C
191	B4		O	cis; mp. >260°C
192	B4		O	.H2O (1:1); trans; mp. 248°C
193	B4		O	cis; mp. 224°C
194	B4		O	trans; mp. 234°C
195	B4		O	cis; mp. 108°C













Co. no.	Ex. no.	R ²	X	physical data
196	B4		O	trans; mp. 127°C
197	B4		O	cis; mp. 150°C
198	B4		O	trans; mp. 90°C
199	B4		O	LC/MS [M+H] ⁺ ; 475.4
200	B4		O	LC/MS [M+H] ⁺ ; 464.3
201	B4		O	LC/MS [M+H] ⁺ ; 523.3
202	B4		O	LC/MS [M+H] ⁺ ; 465.3
203	B4		O	LC/MS [M+H] ⁺ ; 475.4
204	B4		O	LC/MS [M+H] ⁺ ; 465.3
205	B4		O	-
319	B4		O	(cis);.ethanedioate(1:1); mp.:160°C
320	B4		O	(cis); mp.:150°C
321	B4	methoxy	CH ₂	(cis);.HCl(1:1); mp.:118°C
322	B4	n-butyl	O	(cis);.HCl(1:1); mp.:158°C

-73-

Co. no.	Ex. no.	R ²	X	physical data
323	B4		O	-
324	B4		O	-
325	B4		O	-
326	B4		O	-
327	B4		O	-
328	B4		O	-
329	B4		O	-
330	B4		O	-
331	B4		O	-
332	B4		O	-
333	B4		O	-
334	B4		O	-
335	B4		O	-

Co. no.	Ex. no.	R ²	X	physical data
336	B4		O	-
337	B4		O	-
338	B4		O	-
339	B4		O	-
340	B4		O	-
341	B4		O	-
342	B4		O	-
343	B4		O	-
344	B4		O	-
345	B4		O	-
346	B4		O	-
347	B4		O	-
348	B4	CH ₂ OC(=O)CH ₃	O	(cis); mp.:74°C
349	B4		O	-

Co. no.	Ex. no.	R ²	X	physical data
350	B4		O	-
351	B4		O	-
352	B4		O	-
353	B4		O	(A); HCl(1:2).H2O(1:1); mp.:166°C
354	B4		O	(cis)
355	B4		O	-
356	B4		O	-
357	B4		O	-
358	B4		O	-
359	B4		O	-
360	B4		O	-
361	B4		O	-
362	B4		O	-
363	B4		O	-

Co. no.	Ex. no.	R ²	X	physical data
364	B4		O	-
365	B4		O	-
366	B4		O	-
367	B4		O	-
368	B4		O	-
369	B4		O	-
370	B4		O	-
371	B4		O	-
372	B4		O	-
373	B4		O	-
374	B4		O	-
375	B4		O	-














Co. no.	Ex. no.	R ²	X	physical data
376	B4		O	-
377	B4		O	-
378	B4		O	-
379	B4		O	-
380	B4		O	-
381	B4		O	-
382	B4		O	-
383	B4		O	(cis); mp.:148°C
384	B4		O	(trans); mp.:141°C
385	B4		O	mp.:130°C
386	B4		O	(cis); mp.:140°C
387	B4		O	(trans); mp.:155°C

Table 3



Co. no.	Ex. no.	Y.	R¹	physical data
140	B4	O		mp. 220°C
141	B4	O		mp. 213°C
142	B4	O		mp. 148°C
143	B4	O	1-methylcyclohexyl	mp. 195-210°C
144	B4	O	3-methoxycyclohexyl	cis; mp. 156°C
145	B4	O	3-methoxycyclohexyl	trans; mp. 156-163°C
146	B4	O	4-(dimethylethyl)cyclohexyl	mp. 230°C
147	B4	O	4-(methylethoxy)cyclohexyl	mp. 186°C
148	B4	O	4-methylcyclohexyl	trans; mp. 214°C
36	B4	S	4-methoxycyclohexyl	cis; mp. 224°C
37	B4	S	4-methoxycyclohexyl	trans; mp. 220°C
149	B4	O		mp. 188°C
40	B4	O		mp. 192°C
150	B4	O		cis; mp. 226°C
151	B4	O		trans; mp. 226°C
152	B4	O		mp. 213°C
153	B4	O		mp. 200°C














Co. no.	Ex. no.	Y.	R ¹	physical data
154	B4	O		mp. 210°C
155	B4	O	4,4-dimethylcyclohexyl	mp. 242°C
388	B4	O	CH ₂ CH(CH ₃) ₂	mp. 189°C
389	B4	O		mp. 228°C
390	B4	O		mp. 197°C
391	B4	O		mp. 145°C
392	B4	O		mp. 192°C
393	B4	O		(B); mp.:224°C
394	B4	O		(A); mp.:201°C
395	B4	O		(A); mp.:207°C
396	B4	O		mp.:212°C
397	B4	O		(B); mp.:238°C
398	B4	O		mp.:234°C
399	B4	O		(cis); mp.:192°C

Table 4



Co. no.	Ex. no.	R ³	R ⁴	R ⁵	R	physical data
156	B4	ethyl	H	H	OCH ₃	trans; mp. 252°C
157	B4	H	H	H	OCH ₃	(cis + trans); mp. 244°C
158	B4	H	methyl	H	OCH ₃	cis; mp. >260°C
159	B4	methyl	H	H	OCH ₃	cis; mp. 254°C
160	B4	methyl	H	H	OCH ₃	trans; mp. >260°C
161	B4	propyl	H	H	OCH ₃	mp. 208°C
162	B4	propyl	H	H	OCH ₃	trans; mp. 232°C
9	B4	ethyl	H	H	OCH ₃	cis; mp. 224-226°C
43	B5	ethyl	H	CH ₃	OCH ₃	trans; mp. 116°C
42	B5	ethyl	H	CH ₃	OCH ₃	cis; mp. 125°C
44	B6	ethyl	H	CH ₂ -COOC ₂ H ₅	OCH ₃	cis; mp. 152°C
45	B4	ethyl	H	CH ₂ -COOC ₂ H ₅	OCH ₃	trans; mp. 147°C
46	B4	ethyl	H	benzyl	OCH ₃	cis; mp. 137°C
47	B4	ethyl	H	benzyl	OCH ₃	trans; mp. 130°C
50	B7	methyl	H	H	H	mp. 256.1°C
163	B4	ethyl	ethyl	H	OCH ₃	cis; mp. 221°C
164	B4	ethyl	ethyl	H	OCH ₃	cis; mp. 221°C
165	B4	ethyl	ethyl	H	OCH ₃	trans; mp. 215°C
166	B4	ethyl	H		OCH ₃	LC/MS [M+H] ⁺ ; 429.4
167	B4	ethyl	H		OCH ₃	LC/MS [M+H] ⁺ ; 451.3
168	B4	H	H	H	OCH ₃	cis; mp. 106°C
169	B4	ethyl	H		OCH ₃	LC/MS [M+H] ⁺ ; 409.3















Co. no.	Ex. no.	R ³	R ⁴	R ⁵	R	physical data
400	B9	ethyl	H		OCH ₃	-
401	B9	ethyl	H		OCH ₃	-
402	B9	ethyl	H		OCH ₃	-
403	B9	ethyl	H		OCH ₃	-
404	B9	ethyl	H		OCH ₃	-
405	B9	ethyl	H		OCH ₃	-
406	B4	ethyl	H		OCH ₃	-
407	B4	ethyl	H		OCH ₃	-
408	B4	ethyl	H		OCH ₃	-
409	B3b		H	H	OCH ₃	mp.:168°C
410	B4	CH ₂ OCH ₃	H	H	OCH ₃	mp.:194°C
508	B4	ethyl	H		OCH ₃	-
520	B9	ethyl	H		OCH ₃	-

Table 5














Co. no.	Ex. no.	R ⁴	R ¹	X	physical data
33	B4	H	methoxycyclohexyl	CH	cis; mp. 224°C
34	B4	H	methoxycyclohexyl	CH	trans; mp. 185°C
35	B4	H	methoxycyclohexyl	N	cis; mp. 160-172°C
170	B4	H	methoxycyclohexyl	N	trans; mp. 146°C
171	B4	H		N	(B); mp. 165°C
172	B4	H	methylcyclohexyl	N	cis+trans; mp. 143°C
173	B4	ethyl	methoxycyclohexyl	N	cis; mp.:126°C
411	B4	H		N	mp.:109°C
412	B4	H		N	mp.:180°C
413	B4	H		N	(A)
414	B4	H		N	mp.:156°C

Table 6



Co. no.	Ex. no.	R	L	physical data
49	B7	H		-
174	B3b	OCH ₃		cis; mp.115°C
175	B3b	OCH ₃		trans; mp.141°C
176	B3b	OCH ₃		cis; mp.149°C
177	B3b	OCH ₃		mp.126°C
178	B3b	OCH ₃		trans; mp.160°C
179	B3b	OCH ₃		cis; mp.119°C
180	B3b	OCH ₃		trans; mp.124°C
181	B3b	OCH ₃		trans; mp.92°C
206	B3b	OCH ₃		cis; m.p. 144°C

Co. no.	Ex. no.	R	L	physical data
207	B3b	OCH ₃		trans; m.p. 125°C
208	B3b	OCH ₃		cis; m.p. 127°C
209	B3b	OCH ₃		cis; m.p. 101°C
210	B3b	OCH ₃		cis; m.p. 104°C
211	B3b	OCH ₃		trans; m.p. 134°C
212	B4	OCH ₃		cis; m.p. 141°C
213	B4	OCH ₃		trans; m.p. 215°C
214	B4	OCH ₃		cis; m.p. 139°C
215	B3b	OCH ₃		trans
415	B3b	OCH ₃		(cis); mp.:136°C
416	B3b	OCH ₃		(cis)



























Co. no.	Ex. no.	R	L	physical data
417	B4	OCH ₃		(cis); mp.:149°C
418	B3b	OCH ₃		(trans); mp.:132°C
419	B4	OCH ₃		(cis); mp.:217°C
420	B3b	OCH ₃		(cis); HCl(1:1); mp.:200°C
421	B4	OH		(cis); mp.:215°C
422	B4	OH		(trans); mp.:178°C
423	B3b	OCH ₃		mp.:160°C
424	B3b	OCH ₃		(cis); mp.:106°C
425	B3b	OCH ₃		(trans); mp.:120°C
426	B3b	OCH ₃		(cis); mp.:121°C
427	B3b	H		mp.:156°C
428	B3b	OCH ₃		(cis); mp.:156°C
429	B3b	OCH ₃		(trans); mp.:197°C






























Co. no.	Ex. no.	R	L	physical data
430	B3b	CH ₃		(B)
431	B3b	CH ₃		(A)






























Table 7































Co. no.	Ex. no.	R ¹	L	physical data
432	B4			mp.:128°C
433	B4			mp.:175°C
434	B4			mp.:170°C
435	B4			mp.:103°C
436	B4			mp.:151°C
437	B4			(trans); mp.:110°C
438	B4			mp.:150°C
439	B4			mp.:150°C
440	B4			(cis)
441	B4			mp.:166°C

Co. no.	Ex. no.	R ¹	L	physical data
442	B4			mp.:173°C
443	B4			mp.:208°C
444	B4			mp.:149°C
445	B4			mp.:133°C
446	B3b			mp.:150°C
447	B3b			mp.:165°C
448	B3b			mp.:147°C
449	B3b			mp.:154°C
450	B3b			mp.:157°C
451	B4			mp.:190°C
452	B4			mp.:187°C
453	B3b			mp.:200°C
454	B3b			mp.:160°C

Co. no.	Ex. no.	R ¹	L	physical data
455	B3b			mp.:139°C
456	B3b			(A); mp.:174°C
457	B3b			(B); mp.:160°C
458	B3b			mp.:184°C
459	B4			
460	B4			mp.:134°C
461	B4			(B); mp.:156°C
462	B4			mp.:153°C
463	B3b			mp.:161°C
464	B4			mp.:135°C
465	B4			mp.:131°C
466	B3b			.HCl(1:1); mp.:206°C
467	B3d			mp.:142°C
468	B4			.hydrate(1:1); mp.:104°C
469	B3b	dimethylethyl		mp.:104°C

Co. no.	Ex. no.	R ¹	L	physical data
470	B3b			mp.:161°C
472	B3b			mp.:144°C
473	B4			mp.:143°C
474	B4			mp.:196°C
475	B4			mp.:162°C
476	B4			mp.:171°C
477	B4			mp.:155°C
478	B2	trimethylmethyl		mp.:124°C
479	B4			(A); mp.:146°C
480	B4			(B); mp.:162°C
481	B4			(A); mp.:129°C
482	B4			mp.:115°C
483	B2			mp.:187°C
484	B2			mp.:162°C
485	B4			(A); mp.:130°C

Co. no.	Ex. no.	R ¹	L	physical data
486	B4			(A); mp.:124°C
487	B4			(B); mp.:128°C
488	B4			mp.:85°C
489	B2			mp.:150°C
490	B4			(A); mp.:117°C
491	B2			mp.:220°C
492	B4			mp.:136°C
493	B2			mp.:131°C
494	B4			(A); mp.:125°C
495	B4			mp.:135°C
496	B4			mp.:139°C
497	B4			mp.:127°C
498	B4			mp.:195°C
499	B2			mp.:201°C

-91-



























Co. no.	Ex. no.	R ¹	L	physical data
500	B3b			mp.:143°C
501	B3b			mp.:137°C
502	B2			mp.:210°C
503	B3d			mp.:134°C
504	B2			mp.:163°C
505	B4			mp.:142°C
506	B2			mp.:139°C
507	B4			mp.:171°C
512	B3b			-
523	B3b			-

Table 8:

Co. no.	Ex. no.	Structure	physical data
511	B11		-

Co. no.	Ex. no.	Structure	physical data
514	B12		-
515	B13		-
524	B9a		mp.:185°C
471	B15		(E)
526	B14		.HCl(1:1)

C. Pharmacological example

Signal transduction at the cloned rat mGluR1 receptor in CHO cells

CHO cells expressing the mGluR1 receptor were plated in precoated black 96-well plates. The next day, the effect of the present compounds on glutamate-activated intracellular Ca^{2+} increase was evaluated in a fluorescent based assay. The cells were loaded with Fluo-3 AM, plates were incubated for 1 hour at room temperature in the dark, cells were washed and the present compounds were added onto the cells for 20 minutes. After this incubation time, the glutamate-induced Ca^{2+} rise was recorded for each well in function of time using the Fluorescent Image Plate Reader (FLIPR, Molecular Devices Inc.). Relative fluorescence units were recorded and average data graphs of quadruple wells were obtained. Concentration-response curves were constructed based on peak fluorescence (maximum signal between 1 and 90 secondes) for each concentration of tested compound. pIC_{50} values are the $-\log$ values of the concentration of the tested compounds resulting in 50% inhibition of the glutamate-induced intracellular Ca^{2+} rise.

The compounds according to the present invention exhibited a pIC_{50} value of at least 5.

The compounds that are included in the Tables 1-8 exhibited a pIC_{50} value of at least 6.

A particular group of compounds exhibited a pIC_{50} value between 7 and 8. It concerns the compounds listed in Table 9.

Table 9:

Com.nr.	pIC_{50}
463	7.98
441	7.95
334	7.95
22	7.94
421	7.94
15	7.93
440	7.93
139	7.93
178	7.92
338	7.91
87	7.90
462	7.90
394	7.90
423	7.89
21	7.87
220	7.87
479	7.86
483	7.86
485	7.84
9	7.84
110	7.84
248	7.84
341	7.83
163	7.81
433	7.79
238	7.79
224	7.78
437	7.78
498	7.78
449	7.77
242	7.76
346	7.74
182	7.73
486	7.73
447	7.72
7	7.72
175	7.71
475	7.71

Com.nr.	pIC_{50}
281	7.63
487	7.63
299	7.63
431	7.61
98	7.57
464	7.57
446	7.56
251	7.55
484	7.54
494	7.53
128	7.52
344	7.52
161	7.49
298	7.48
454	7.45
456	7.45
277	7.44
91	7.43
356	7.42
229	7.41
333	7.41
326	7.41
369	7.40
430	7.39
435	7.38
35	7.36
228	7.36
429	7.36
117	7.35
291	7.35
313	7.35
280	7.34
460	7.34
482	7.34
343	7.33
425	7.32
473	7.32
287	7.31

Com.nr.	pIC_{50}
89	7.25
108	7.25
373	7.25
255	7.23
527	7.23
303	7.22
296	7.22
221	7.21
193	7.21
14	7.20
131	7.19
438	7.19
148	7.18
496	7.18
236	7.17
332	7.17
481	7.16
191	7.16
457	7.14
20	7.14
145	7.13
268	7.13
512	7.13
474	7.13
10	7.11
307	7.11
426	7.11
466	7.10
97	7.08
83	7.08
434	7.08
300	7.08
199	7.07
290	7.06
112	7.05
348	7.05
286	7.03
442	7.03

-94-

Com.nr.	pIC ₅₀
480	7.71
213	7.70
239	7.70
241	7.67
461	7.65
115	7.64
445	7.63





Com.nr.	pIC ₅₀
448	7.31
243	7.29
323	7.28
159	7.28
289	7.27
184	7.26
436	7.26







Com.nr.	pIC ₅₀
422	7.02
283	7.02
318	7.02
36	7.00
396	7.00








A particular group of compounds exhibited a pIC₅₀ value of at least 8. It concern the compounds listed in Table 10.







Table 10 :







5


Comp. nr.	Structure	pIC ₅₀
416	 (CIS)	8.587
27	 (CIS)	8.527
174	 (CIS)	8.49
506		8.48

Comp. nr.	Structure	pIC ₅₀
25	 (CIS)	8.45
4	 (CIS)	8.4
19	 (CIS)	8.38
429	 (CIS)	8.38
424	 (CIS)	8.355
176	 (CIS)	8.33

Comp. nr.	Structure	pIC ₅₀
210	 (CIS)	8.315
114	 (CIS)	8.28
488		8.27
504		8.27
477		8.25
432		8.237
214	 (CIS)	8.233

Comp. nr.	Structure	pIC50
465		8.145
135	 (CIS)	8.14
420	 (CIS) Hydrochloride (1:1)	8.135
292	 (CIS)	8.13
427		8.115
208	 (CIS)	8.095

Comp. nr.	Structure	pIC50
419	 (CIS)	8.065
455		8.055
418	 (TRANS)	8.045
497		8.025
439		8.023
237		8.01

Comp. nr.	Structure	pIC ₅₀
499		8

Cold allodynia test in rats with a Bennett ligation.

Surgery:

Male SD rats, weighing 240 - 280 g at the time of surgery were used.

- For surgery, the animals were anaesthetised with Thalamonal (1 ml; subcutane) and sodium pentobarbital (40 mg/kg; intraperitoneal (IP)). The common sciatic nerve of the left hindpaw was exposed at the level of the middle of the thigh by blunt dissection through the biceps femoris. Proximal to the sciatic's trifurcation, about 7 mm of nerve was freed and four loose ligatures with 4.0 chromic gut were placed around the sciatic nerve. Great care was taken to tie the ligatures such that the diameter of the nerve was barely constricted. After surgery, the animals received 1.25 mg/kg naloxone IP.

Cold plate testing:

- Cold plate testing was performed on a metal plate of 30 X 30 cm with transparent acrylic walls around it. The cold plate was cooled to 0.0 (\pm 0.5) °C using a Julabo F25 cooler. For testing, the animal was placed on the cold plate and the duration of lifting of both the left and the right hindpaw was measured during 5 minutes. The difference in lifting time between the ligated and non-ligated paw was calculated.

Testing procedure:

- At least one week after the operation, animals were placed on the cold plate test and a pre-drug measurement was taken. Animals having a difference in lifting time > 25 secondes between the ligated and the non-ligated paw were selected for drug testing. These selected animals were injected IP with a compound of the present invention and were retested after 60 minutes (post drug test). The results obtained during the post drug test were expressed as a percentage of those of the predrug test.

The data were analysed in terms of all or none criterion (based on the results of control animals) with the limits being:

-100-

Inhibition: $(\text{post-drug/pre-drug}) * 100 < 40 \%$


Antagonism: $(\text{post-drug/pre-drug}) * 100 < 25 \%$

Compound (27) showed antagonism at a dose of 2.5 mg/kg bodyweight.

-101-

Claims

1. A compound of formula




an *N*-oxide form, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochemically isomeric form thereof, wherein

X represents O; C(R⁶)₂ with R⁶ being hydrogen, aryl or C₁₋₆alkyl optionally substituted with amino or mono- or di(C₁₋₆alkyl)amino; S or N-R⁷ with R⁷ being amino or hydroxy;

R¹ represents C₁₋₆alkyl; aryl; thienyl; quinolinyl; cycloC₃₋₁₂alkyl or (cycloC₃₋₁₂alkyl)C₁₋₆alkyl, wherein the cycloC₃₋₁₂alkyl moiety optionally may contain a double bond and wherein one carbon atom in the cycloC₃₋₁₂alkyl moiety may be replaced by an oxygen atom or an NR⁸-moiety with R⁸ being hydrogen, benzyl or C₁₋₆alkyloxycarbonyl; wherein one or more hydrogen atoms in a C₁₋₆alkyl-moiety or in a cycloC₃₋₁₂alkyl-moiety optionally may be replaced by C₁₋₆alkyl, hydroxyC₁₋₆alkyl, haloC₁₋₆alkyl, aminoC₁₋₆alkyl, hydroxy, C₁₋₆alkyloxy, arylC₁₋₆alkyloxy, halo, C₁₋₆alkyloxycarbonyl, aryl, amino, mono- or di(C₁₋₆alkyl)amino, C₁₋₆alkyloxycarbonylamino, halo, piperazinyl, pyridinyl, morpholinyl, thienyl or a bivalent radical of formula -O-, -O-CH₂-O or -O-CH₂-CH₂-O-;

or a radical of formula (a-1)



a-1

wherein Z₁ is a single covalent bond, O, NH or CH₂;

Z₂ is a single covalent bond, O, NH or CH₂;

n is an integer of 0, 1, 2 or 3;

- 102 -

and wherein each hydrogen atom in the phenyl ring independently may optionally be replaced by halo, hydroxy, C₁₋₆alkyl, C₁₋₆alkyloxy or hydroxyc₁₋₆alkyl;


or X and R¹ may be taken together with the carbon atom to which X and R¹ are attached to form a radical of formula (b-1), (b-2) or (b-3);



b-1



b-2



b-3

R² represents hydrogen; halo; cyano; C₁₋₆alkyl; C₁₋₆alkyloxy; C₁₋₆alkylthio; C₁₋₆alkylcarbonyl; C₁₋₆alkyloxy carbonyl; C₁₋₆alkylcarbonyloxy C₁₋₆alkyl; C₂₋₆alkenyl; hydroxyc₂₋₆alkenyl; C₂₋₆alkynyl; hydroxyc₂₋₆alkynyl; tri(C₁₋₆alkyl)silane C₂₋₆alkynyl; amino; mono- or di(C₁₋₆alkyl)amino; mono- or di(C₁₋₆alkyloxy C₁₋₆alkyl)amino; mono- or di(C₁₋₆alkylthio C₁₋₆alkyl)amino; aryl; aryl C₁₋₆alkyl; aryl C₂₋₆alkynyl; C₁₋₆alkyloxy C₁₋₆alkylamino C₁₋₆alkyl; aminocarbonyl optionally substituted with C₁₋₆alkyl, C₁₋₆alkyloxy C₁₋₆alkyl, C₁₋₆alkyloxy carbonyl C₁₋₆alkyl or pyridinyl C₁₋₆alkyl; a heterocycle selected from thienyl, furanyl, pyrrolyl, thiazolyl, oxazolyl, imidazolyl, isothiazolyl, isoxazolyl, pyrazolyl, pyridyl, pyrazinyl, pyridazinyl, pyrimidinyl, piperidinyl and piperazinyl, optionally N-substituted with C₁₋₆alkyloxy C₁₋₆alkyl, morpholinyl, thiomorpholinyl, dioxanyl or dithianyl; a radical -NH-C(=O)R⁹ wherein R⁹ represents C₁₋₆alkyl optionally substituted with cycloC₃₋₁₂alkyl, C₁₋₆alkyloxy, C₁₋₆alkyloxy carbonyl, aryl, aryloxy, thienyl, pyridinyl, mono- or di(C₁₋₆alkyl)amino, C₁₋₆alkylthio, benzylthio, pyridinylthio or pyrimidinylthio; cycloC₃₋₁₂alkyl; cyclohexenyl; amino; arylcycloC₃₋₁₂alkylamino; mono- or di(C₁₋₆alkyl)amino; mono- or di(C₁₋₆alkyloxy carbonyl C₁₋₆alkyl)amino; mono- or di(C₁₋₆alkyloxy carbonyl)amino; mono- or di(C₂₋₆alkenyl)amino; mono- or di(aryl C₁₋₆alkyl)amino; mono- or diarylamino; aryl C₂₋₆alkenyl; furanyl C₂₋₆alkenyl; piperidinyl; piperazinyl; indolyl; furyl; benzofuryl; tetrahydrofuryl; indenyl; adamantyl; pyridinyl; pyrazinyl; aryl; aryl C₁₋₆alkylthio or a radical of formula (a-1) ;

-103-

a sulfonamid-NH-SO₂-R¹⁰ wherein R¹⁰ represents C₁₋₆alkyl, mono- or poly haloC₁₋₆alkyl, arylC₁₋₆alkyl, arylC₂₋₆alkenyl, aryl, quinolinyl, isoxazolyl or di(C₁₋₆alkyl)amino;

- 5 R³ and R⁴ each independently represent hydrogen; halo; hydroxy; cyano; C₁₋₆alkyl; C₁₋₆alkyloxy; C₁₋₆alkyloxyC₁₋₆alkyl; C₁₋₆alkylcarbonyl; C₁₋₆alkyloxy carbonyl; C₂₋₆alkenyl; hydroxyC₂₋₆alkenyl; C₂₋₆alkynyl; hydroxyC₂₋₆alkynyl; tri(C₁₋₆alkyl)silaneC₂₋₆alkynyl; amino; mono- or di(C₁₋₆alkyl)amino; mono- or di(C₁₋₆alkyloxyC₁₋₆alkyl)amino; mono- or di(C₁₋₆alkylthioC₁₋₆alkyl)amino; aryl;
- 10 morpholinylC₁₋₆alkyl or piperidinylC₁₋₆alkyl; or
- R² and R³ may be taken together to form -R²-R³-, which represents a bivalent radical of formula -(CH₂)₃-, -(CH₂)₄-, -(CH₂)₅-, -(CH₂)₆-, -CH=CH-CH=CH-, -Z₄-CH=CH-, -CH=CH-Z₄-, -Z₄-CH₂-CH₂-CH₂-, -CH₂-Z₄-CH₂-CH₂-, -CH₂-CH₂-Z₄-CH₂-,
- 15 -CH₂-CH₂-CH₂-Z₄-, -Z₄-CH₂-CH₂-, -CH₂-Z₄-CH₂- or -CH₂-CH₂-Z₄-, with Z₄ being O, S, SO₂ or NR¹¹ wherein R¹¹ is hydrogen, C₁₋₆alkyl, benzyl or C₁₋₆alkyloxy carbonyl; and wherein each bivalent radical is optionally substituted with C₁₋₆alkyl.

or R³ and R⁴ may be taken together to form a bivalent radical of formula

- 20 -CH=CH-CH=CH- or -CH₂-CH₂-CH₂-CH₂-;

- R⁵ represents hydrogen; cycloC₃₋₁₂alkyl; piperidinyl; oxo-thienyl; tetrahydrothienyl, arylC₁₋₆alkyl; C₁₋₆alkyloxyC₁₋₆alkyl; C₁₋₆alkyloxy carbonylC₁₋₆alkyl or C₁₋₆alkyl optionally substituted with a radical C(=O)NR_xR_y, in which R_x and R_y, each independently are hydrogen, cycloC₃₋₁₂alkyl, C₂₋₆alkynyl or C₁₋₆alkyl optionally
- 25 substituted with cyano, C₁₋₆alkyloxy, C₁₋₆alkyloxy carbonyl, furanyl, pyrrolidinyl, benzylthio, pyridinyl, pyrrolyl or thienyl;

Y represents O or S;

or Y and R⁵ may be taken together to form =Y-R⁵- which represents a radical of formula

- 30 -CH=N-N= (c-1);
 -N=N-N= (c-2); or
 -N-CH=CH- (c-3);

aryl represents phenyl or naphthyl optionally substituted with one or more substituents selected from halo, hydroxy, C₁₋₆alkyl, C₁₋₆alkyloxy, phenyloxy, nitro, amino, thio,


35 C₁₋₆alkylthio, haloC₁₋₆alkyl, polyhaloC₁₋₆alkyl, polyhaloC₁₋₆alkyloxy, hydroxyC₁₋₆alkyl, C₁₋₆alkyloxyC₁₋₆alkyl, aminoC₁₋₆alkyl, mono- or di(C₁₋₆alkyl)amino; mono- or di(C₁₋₆alkyl)aminoC₁₋₆alkyl, cyano, -CO-R¹², -CO-OR¹³,

-104-

-NR¹³SO₂R¹², -SO₂-NR¹³R¹⁴, -NR¹³C(O)R¹², -C(O)NR¹³R¹⁴, -SOR¹², -SO₂R¹²;
 wherein each R¹², R¹³ and R¹⁴ independently represent C₁₋₆alkyl; cycloC₃₋₆alkyl;
 phenyl; phenyl substituted with halo, hydroxy, C₁₋₆alkyl, C₁₋₆alkyloxy,
 haloC₁₋₆alkyl, polyhaloC₁₋₆alkyl, furanyl, thienyl, pyrrolyl, imidazolyl, thiazolyl or
 oxazolyl;

and when the R¹-C(=X) moiety is linked to another position than the 7 or 8 position,
 then said 7 and 8 position may be substituted with R¹⁵ and R¹⁶ wherein either one or
 both of R¹⁵ and R¹⁶ represents C₁₋₆alkyl, C₁₋₆alkyloxy or R¹⁵ and R¹⁶ taken together may
 form a bivalent radical of formula -CH=CH-CH=CH-.

2. A compound according to claim 1, characterized in that,
 X represents O; C(R⁶)₂ with R⁶ being hydrogen or aryl ; or N-R⁷ with R⁷ being amino
 or hydroxy;
 R¹ represents C₁₋₆alkyl, aryl; thienyl; quinolinyl; cycloC₃₋₁₂alkyl or
 (cycloC₃₋₁₂alkyl)C₁₋₆alkyl, wherein the cycloC₃₋₁₂alkyl moiety optionally may
 contain a double bond and wherein one carbon atom in the cycloC₃₋₁₂alkyl moiety
 may be replaced by an oxygen atom or an NR⁸-moiety with R⁸ being benzyl or
 C₁₋₆alkyloxycarbonyl ; wherein one or more hydrogen atoms in a C₁₋₆alkyl-moiety
 or in a cycloC₃₋₁₂alkyl-moiety optionally may be replaced by C₁₋₆alkyl,
 haloC₁₋₆alkyl, hydroxy, C₁₋₆alkyloxy, arylC₁₋₆alkyloxy, halo, aryl, mono- or
 di(C₁₋₆alkyl)amino, C₁₋₆alkyloxycarbonylamino, halo, piperazinyl, pyridinyl,
 morpholinyl, thienyl or a bivalent radical of formula -O- or -O-CH₂-CH₂-O-;
 or a radical of formula (a-1)



a-1

wherein Z₁ is a single covalent bond, O or CH₂;


Z₂ is a single covalent bond, O or CH₂;

n is an integer of 0, 1, or 2 ;

and wherein each hydrogen atom in the phenyl ring independently
 may optionally be replaced by halo or hydroxy;

or X and R¹ may be taken together with the carbon atom to which X and R¹ are
 attached to form a radical of formula (b-1), (b-2) or (b-3);

-105-



- R^2 represents hydrogen; halo; cyano; C_{1-6} alkyl; C_{1-6} alkyloxy; C_{1-6} alkylthio; C_{1-6} alkylcarbonyl; C_{1-6} alkyloxycarbonyl; C_{2-6} alkenyl; hydroxy C_{2-6} alkenyl;
- 5 C_{2-6} alkynyl; hydroxy C_{2-6} alkynyl; tri(C_{1-6} alkyl)silane C_{2-6} alkynyl; amino; mono- or di(C_{1-6} alkyl)amino; mono- or di(C_{1-6} alkyloxy C_{1-6} alkyl)amino; mono- or di(C_{1-6} alkylthio C_{1-6} alkyl)amino; aryl; aryl C_{1-6} alkyl; aryl C_{2-6} alkynyl; C_{1-6} alkyloxy C_{1-6} alkylamino C_{1-6} alkyl; aminocarbonyl optionally substituted with C_{1-6} alkyloxycarbonyl C_{1-6} alkyl;
- 10 a heterocycle selected from thienyl, furanyl, thiazolyl and piperidinyl, optionally N-substituted with morpholinyl or thiomorpholinyl; a radical $-NH-C(=O)R^9$ wherein R^9 represents C_{1-6} alkyl optionally substituted with cyclo C_{3-12} alkyl, C_{1-6} alkyloxy, C_{1-6} alkyloxycarbonyl, aryl, aryloxy, thienyl, pyridinyl, mono- or di(C_{1-6} alkyl)amino, C_{1-6} alkylthio, benzylthio, pyridinylthio or
- 15 pyrimidinylthio; cyclo C_{3-12} alkyl; cyclohexenyl; amino; arylcyclo C_{3-12} alkylamino; mono-or-di(C_{1-6} alkyl)amino; mono- or di(C_{1-6} alkyloxycarbonyl C_{1-6} alkyl)amino; mono- or di(C_{1-6} alkyloxycarbonyl)amino; mono-or di(C_{2-6} alkenyl)amino; mono- or di(aryl C_{1-6} alkyl)amino; mono- or diarylamino; aryl C_{2-6} alkenyl; furanyl C_{2-6} alkenyl; piperididynyl; piperazinyl; indolyl; furyl; benzofuryl; tetrahydrofuryl; indenyl;
- 20 adamantyl; pyridinyl; pyrazinyl; aryl or a radical of formula (a-1); a sulfonamid $-NH-SO_2-R^{10}$ wherein R^{10} represents C_{1-6} alkyl, mono- or poly halo C_{1-6} alkyl, aryl C_{1-6} alkyl or aryl;
- R^3 and R^4 each independently represent hydrogen; C_{1-6} alkyl; C_{1-6} alkyloxy C_{1-6} alkyl; C_{1-6} alkyloxycarbonyl; or
- 25 R^2 and R^3 may be taken together to form $-R^2-R^3-$, which represents a bivalent radical of formula $-(CH_2)_4-$, $-(CH_2)_5-$, $-Z_4-CH=CH-$, $-Z_4-CH_2-CH_2-CH_2-$ or $-Z_4-CH_2-CH_2-$, with Z_4 being O, S, SO_2 or NR^{11} wherein R^{11} is hydrogen, C_{1-6} alkyl, benzyl or C_{1-6} alkyloxycarbonyl; and wherein each bivalent radical is optionally substituted with C_{1-6} alkyl;
- 30 or R^3 and R^4 may be taken together to form a bivalent radical of formula $-CH=CH-CH=CH-$ or $-CH_2-CH_2-CH_2-CH_2-$;
- R^5 represents hydrogen; piperidinyl; oxo-thienyl; tetrahydrothienyl, aryl C_{1-6} alkyl; C_{1-6} alkyloxycarbonyl C_{1-6} alkyl or C_{1-6} alkyl optionally substituted with a radical

-106-

$C(=O)NR_xR_y$, in which R_x and R_y , each independently are hydrogen, cyclo C_{3-12} alkyl, C_{2-6} alkynyl or C_{1-6} alkyl optionally substituted with cyano, C_{1-6} alkyloxy or C_{1-6} alkyloxycarbonyl;

Y represents O or S;

- 5 or Y and R^5 may be taken together to form $=Y-R^5$ - which represents a radical of formula

$-CH=N-N=$ (c-1); or

$-N=N-N=$ (c-2);

- aryl represents phenyl or naphthyl optionally substituted with one or more substituents
10 selected from halo, C_{1-6} alkyloxy, phenyloxy, mono- or di(C_{1-6} alkyl)amino and cyano;

and when the $R^1-C(=X)$ moiety is linked to another position than the 7 or 8 position, then said 7 and 8 position may be substituted with R^{15} and R^{16} wherein either one or both of R^{15} and R^{16} represents C_{1-6} alkyl or R^{15} and R^{16} taken together may form a
15 bivalent radical of formula $-CH=CH-CH=CH-$.

3. A compound according to claim 1, characterized in that,

X represents O;

- R^1 represents C_{1-6} alkyl; cyclo C_{3-12} alkyl or (cyclo C_{3-12} alkyl) C_{1-6} alkyl, wherein one or
20 more hydrogen atoms in a C_{1-6} alkyl-moiety or in a cyclo C_{3-12} alkyl-moiety optionally may be replaced by C_{1-6} alkyloxy, aryl, halo or thienyl;

R^2 represents hydrogen; halo; C_{1-6} alkyl or amino;

R^3 and R^4 each independently represent hydrogen or C_{1-6} alkyl; or

- R^2 and R^3 may be taken together to form $-R^2-R^3-$, which represents a bivalent radical of
25 formula $-Z_4-CH_2-CH_2-CH_2-$ or $-Z_4-CH_2-CH_2-$ with Z_4 being O or NR^{11} wherein R^{11} is C_{1-6} alkyl; and wherein each bivalent radical is optionally substituted with C_{1-6} alkyl;
or R^3 and R^4 may be taken together to form a bivalent radical of formula
 $-CH_2-CH_2-CH_2-CH_2-$;

- 30 R^5 represents hydrogen;


Y represents O; and

aryl represents phenyl optionally substituted with halo.


4. A compound as claimed in claim 1, characterized in that, the $R^1-C(=X)$ moiety is
35 linked to the quinoline or quinolinone moiety in position 6.

5. A compound as claimed in claim 1 for use as a medicine.

6. Use of a compound as defined in claims 1 to 4 in the manufacture of a medicament for treating or preventing glutamate-induced diseases of the central nervous system.
7. Use according to claim 6, characterized in that, the glutamate-induced disease of the central nervous system is drug addiction or abstinence (dependence, opioid tolerance, opioid withdrawal), hypoxic, anoxic and ischemic injuries (ischemic stroke, cardiac arrest), pain (neuropathic pain, inflammatory pain, hyperalgesia), hypoglycemia, diseases related to neuronal damage, brain trauma, head trauma, spinal cord injury, myelopathy, dementia, anxiety, schizophrenia, depression, impaired cognition, amnesia, bipolar disorders, conduct disorders, Alzheimer's disease, vascular dementia, mixed (Alzheimer's and vascular) dementia, Lewy Body disease, delirium or confusion, Parkinson's disease, Huntington's disease, Down syndrome, epilepsy, aging, Amyotrophic Lateral Sclerosis, multiple sclerosis, AIDS (Acquired Immune Deficiency Syndrome) and AIDS related complex (ARC).
8. A pharmaceutical composition comprising a pharmaceutically acceptable carrier, and as active ingredient a therapeutically effective amount of a compound as defined in claims 1 to 4.
9. A process of preparing a composition as claimed in claim 8, characterized in that, a pharmaceutically acceptable carrier is intimately mixed with a therapeutically effective amount of a compound as described in claims 1 to 4.
10. A process of preparing a compound of formula (I-A) or (I-B) as claimed in claim 1, characterized by
- a) oxidizing an intermediate of formula (II) in the presence of a suitable oxidizing agent




- with R¹ as defined in claim 1 and Q representing the quinoline or the quinolinone moiety of a compound of formula (I-A) or (I-B); or
- b) reacting an intermediate of formula (III) with an intermediate of formula (IV)




-108-


with R^1 as defined in claim 1, Q representing the quinoline or the quinolinone moiety of a compound of formula (I-A) or (I-B) and W_1 being a suitable leaving group; or
c) reacting an intermediate of formula (V) with an intermediate of formula (IV)



- 5 with R^1 as defined in claim 1, Q representing the quinoline or the quinolinone moiety of a compound of formula (I-A) or (I-B) and W_1 being a suitable leaving group; or
d) reacting an intermediate of formula (VI) with an intermediate of formula (VII) in the presence of a suitable acid



- 10 with R^{1a} being defined as R^1 according to claim 1 provided that R^1 is linked to the carbonyl moiety via a oxygen atom and Q representing the quinoline or the quinolinone moiety of a compound of formula (I-A) or (I-B); or
e) reacting an intermediate of formula (VIII) in the presence of a suitable acid



- 15 with R^1 , X, R^3 and R^4 defined as in claim 1;

and, if desired, converting compounds of formula (I-A) or (I-B) into each other following art-known transformations; and further, if desired, converting the compounds of formula (I-A) or (I-B), into a therapeutically active non-toxic acid addition salt by
20 treatment with an acid, or conversely, converting the acid addition salt form into the free base by treatment with alkali; and, if desired, preparing stereochemically isomeric forms, quaternary amines or *N*-oxide forms thereof.

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP 01/11135

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D215/18 C07D215/22 C07D215/14 C07D215/38 C07F7/10
 C07D215/48 C07D409/04 C07D471/04 C07D215/36 C07D405/04
 C07D409/12 C07D401/12 C07D491/04 C07D495/04 A61K31/47

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D C07F A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 4 476 132 A (GOESCHKE RICHARD ET AL) 9 October 1984 (1984-10-09) see general formula and examples ---	1,2,4-6, 8,9
X	WO 97 44339 A (GOULET MARK ;JIANG JINLONG (US); ALLEN ERIC E (US); DEVITA ROBERT) 27 November 1997 (1997-11-27) see formula 5, page 13 and definitions of R5-R8 ---	1,2,4
X	DE 198 59 750 A (HENKEL KGAA) 29 June 2000 (2000-06-29) see general formula and definitions of R1 --- -/-	1-4



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

Z document member of the same patent family

Date of the actual completion of the international search

26 November 2001

Date of mailing of the international search report

30/11/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax (+31-70) 340-3016

Authorized officer

Scruton-Evans, I

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/EP 01/11135

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61P25/00 C07D405/06 //(C07D471/04, 249:00, 221:00),
(C07D471/04, 257:00, 221:00), (C07D491/04, 311:00, 221:00),
(C07D495/04, 335:00, 221:00)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 00 12498 A (GRECA SUSAN DEBORAH ;LYSSIKATOS JOSEPH PETER (US); YANG BINGWEI VE) 9 March 2000 (2000-03-09) see intermediates of scheme 2, page 9(compounds 25 on page 17 and page 15, 3a) ---	1-4
X	WO 00 39082 A (JANSSEN PHARMACEUTICA NV ;ANGIBAUD PATRICK RENE (FR); VENET MARC G) 6 July 2000 (2000-07-06) see intermediates of page 23, A9, A8 page 22, 18, page 24, intermediate 22, 26, 30, 34 and pages 36-44 --- -/-	1-4

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
 E earlier document but published on or after the international filing date
 L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
 O document referring to an oral disclosure, use, exhibition or other means
 P document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
 X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
 Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
 Z document member of the same patent family

Date of the actual completion of the international search

26 November 2001

Date of mailing of the international search report

Name and mailing address of the ISA
 European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Scruton-Evans, I

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	T.P DABHI ET AL: "Potential Antimicrobial Agents" INDIAN JOURNAL OF HETEROCYCLIC CHEMISTRY, vol. 2, no. 2, 1992, pages 137-138, XP000943434 See experimental and all of the R definitions in Table 1 ----	1-4
X	D.J. BHATT ET AL: "Studies on Chalcones" JOURNAL OF THE INDIAN CHEMICAL SOCIETY, vol. 61, no. 9, 1984, pages 816-818, XP000943275 See the compounds of formula I in Table 1 ----	1-4
A	WO 99 03822 A (KOZIKOWSKI ALAN P ;UNIV GEORGETOWN (US); ARALDI GIAN LUCA (US); ST) 28 January 1999 (1999-01-28) the whole document ----	1-10
A	WO 99 26927 A (STORMANN THOMAS M ;DELMAR ERIC G (US); MOE SCOTT T (US); SMITH DAR) 3 June 1999 (1999-06-03) cited in the application the whole document ----	1-10
P,X	WO 01 66143 A (WATANABE HIROYUKI ;SANTO TAKASHI (JP); TARUI NAOKI (JP); MORI MASA) 13 September 2001 (2001-09-13) compound 1H-Pyrrolo[2,3b]quinolin-4-amine, 6-(2-benz ofuranyl)-2,3-dihydro-1-(phenylmethyl)-, monohydrochloride, RN 359582-59-5 ----	1
X	PATENT ABSTRACTS OF JAPAN vol. 2000, no. 09, 13 October 2000 (2000-10-13) & JP 2000 169450 A (KYORIN PHARMACEUT CO LTD), 20 June 2000 (2000-06-20) see abstract and examples, especially page 11 -----	1-10

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 01/11135

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 4476132	A	09-10-1984	AR 240044 A1	31-01-1990
			AT 27451 T	15-06-1987
			AU 560003 B2	26-03-1987
			AU 8181982 A	30-09-1982
			CY 1412 A	22-04-1988
			DE 3276432 D1	02-07-1987
			DK 130382 A ,B,	25-09-1982
			EP 0062001 A2	06-10-1982
			ES 510685 D0	16-10-1983
			ES 8400092 A1	01-01-1984
			ES 523337 D0	01-03-1985
			ES 8503661 A1	16-06-1985
			ES 523338 D0	01-03-1985
			ES 8503662 A1	16-06-1985
			ES 523339 D0	01-03-1985
			ES 8503663 A1	16-06-1985
			ES 523340 D0	01-03-1985
			ES 8503664 A1	16-06-1985
			ES 523341 D0	16-02-1985
			ES 8503334 A1	01-06-1985
			ES 523342 D0	01-03-1985
			ES 8503665 A1	16-06-1985
			FI 820983 A ,B,	25-09-1982
			GB 2095668 A ,B	06-10-1982
			GR 78345 A1	26-09-1984
			HK 3988 A	22-01-1988
			HU 192103 B	28-05-1987
			IE 53158 B1	03-08-1988
			JP 6006576 B	26-01-1994
			JP 57192366 A	26-11-1982
			MY 80687 A	31-12-1987
			NO 820959 A ,B,	27-09-1982
			NZ 200106 A	31-07-1985
			PT 74634 A ,B	01-04-1982
			ZA 8201957 A	23-02-1983
WO 9744339	A	27-11-1997	AU 710926 B2	30-09-1999
			AU 3008997 A	09-12-1997
			CA 2254769 A1	27-11-1997
			EP 0901489 A1	17-03-1999
			JP 2000511532 T	05-09-2000
			WO 9744339 A1	27-11-1997
DE 19859750	A	29-06-2000	US 6150352 A	21-11-2000
			DE 19859750 A1	29-06-2000
			AU 1978800 A	31-07-2000
			WO 0038633 A1	06-07-2000
WO 0012498	A	09-03-2000	EP 1139988 A1	10-10-2001
			AU 4925199 A	21-03-2000
			BR 9913315 A	22-05-2001
			EP 1107962 A1	20-06-2001
WO 0039082	A	06-07-2000	WO 0012498 A1	09-03-2000
			AU 2795300 A	31-07-2000
			BR 9916827 A	16-10-2001
			WO 0039082 A2	06-07-2000
			EP 1140935 A2	10-10-2001

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 01/11135

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0039082	A		NO 20013088 A	21-06-2001
WO 9903822	A	28-01-1999	AU 8575498 A EP 1000015 A1 JP 2001515839 T WO 9903822 A1 US 6204292 B1 US 2001018429 A1	10-02-1999 17-05-2000 25-09-2001 28-01-1999 20-03-2001 30-08-2001
WO 9926927	A	03-06-1999	AU 1531799 A CN 1285820 T EP 1037878 A2 WO 9926927 A2	15-06-1999 28-02-2001 27-09-2000 03-06-1999
WO 0166143	A	13-09-2001	WO 0166143 A1	13-09-2001
JP 2000169450	A	20-06-2000	NONE	